From the Departments of Psychology (Ms. Zhao, Drs. Russell, Wesley, and Porter) and Hematology (Mss. Johnson and Pullen, Dr. Hankins), St. Jude Children’s Research Hospital, Memphis, TN.

Abstract

• Background: Children with sickle cell disease (SCD) are surviving into adulthood. Mastery of disease knowledge may facilitate treatment continuity in adult care.
• Objective: To assess the accuracy and extent of medical history knowledge among adolescents with SCD through the use of a personal health record (PHR) form.
• Methods: 68 adolescent patients with SCD (52.9% male; mean age, 16.8 years; 100% African American) completed a PHR listing significant prior medical events (eg, disease complications, diagnostic evaluations, treatments). Responses were compared against participants’ electronic medical record. An agreement percentage was calculated to determine accuracy of knowledge.
• Results: Most adolescents correctly reported their sickle cell genotype (100%), usage of penicillin (97.1%), prior hospitalizations (96.5%), history of prior blood transfusions (93.8%), usage of hydroxyurea (88.2%), and allergies (85.2%). Fewer adolescents accurately reported usage of opioids (52.9%), prior acute chest syndrome events (50.9%), baseline hemoglobin (41.8%), and hepatitis (43.3%), pneumovax (30.2%), and menactra (14.5%) vaccinations.
• Conclusion: Adolescents are aware of most but not all aspects of their medical history. The present findings can inform areas of knowledge deficits. Future targeted interventions for transition education and preparation may be tailored based on individual disease knowledge.

Sickle cell disease (SCD) is a genetic disorder characterized by abnormal sickle hemoglobin resulting in chronic hemolytic anemia and vaso-occlusion [1]. More than 95% of children with SCD in the United States survive into adulthood; however, young adults (YAs) are at risk for mortality shortly after transfer to adult health care [2–5]. Specifically, YAs with SCD (ages 18 to 30) have increased hospital utilization, emergency department visits, and mortality compared to other age-groups [4–7]. During this critical period, transition preparation that includes improving disease literacy and ensuring medical history knowledge may be necessary for optimal outcomes.

In the extant YA literature, significant gaps in medical history knowledge during the transition period were observed in pediatric cancer and inflammatory bowel disease patients [8,9]. YAs often require multidisciplinary management of their chronic disease complications [10]. Therefore, possessing comprehensive knowledge of personal health history may facilitate communication with different adult care providers and promote continuity of care. In the SCD transition literature, transition readiness measures have been developed to assess several aspects of knowledge, including medical and disease knowledge; however, these measures are primarily self-reported perceptions of knowledge and do not evaluate the accuracy of knowledge [11,12]. The current pilot study addresses this gap with the aim of assessing medical history knowledge accuracy in adolescents with SCD.

Methods

Participants

From March 2011 to January 2014, adolescents (aged 15–18 years) with SCD (any genotype) were approached during their regular health maintenance visits by hematology social workers. They were invited to complete the Personal Health Record (PHR) as an implementation effort of transition preparation within our pediatric SCD program.

Personal Health Record

The PHR was developed through literature review and discussions with area adult hematologists. The form was modeled after first visit intake forms used in adult hematology clinics. It was reviewed by the hematology medical team and the institution’s patient education committee. Prior to implementation, the form was piloted to obtain patient feedback on format and content. The PHR consists of 33 questions with 168 possible items/data points covering 12 domains: personal information (eg, contact information, SCD genotype), health provider information, personal health history (ie, health diagnoses), blood transfusion history, sickle cell pain events, hospitalization history in the previous year, diagnostic testing history (eg, laboratory tests), current medications, immunizations, advance directives, resource information (eg, disability benefits), and activities of daily living. Some questions required patients to check “Yes” or “No” (eg, “Have you been hospitalized in the past year? Have you received flu vaccine?”) while some required a written response (eg, “What medicines do you currently take?”).

Adolescents were instructed to complete the PHR independently without the help of their caregivers. After completing the form, the social worker reviewed the answers and/or asked participants’ perspectives about communicating health information to providers. A copy of the completed PHR was provided to the adolescent to promote continued education regarding medical history knowledge. The retrospective review of the PHR answers and participants’ characteristics was approved by the institutional review board with a waiver of consent from participants.

Statistical Methods

PHR answers were compared with each individual’s electronic medical record (EMR) for accuracy of responses. PHR responses were considered accurate only if they matched the information in the EMR. PHR items absent in the EMR were not coded (inability to verify the accuracy of responses) to capture the most accurate depiction of adolescents’ medical history knowledge. Coding was checked by at least 2 coders for response accuracy. Due to lack of EMR information for certain items, we could not verify the accuracy of many PHR items. Therefore, only items with at least 75% of data verified (across all patients who completed the PHR) were included in subsequent analyses.

Using SPSS (version 18), an agreement percentage was calculated for each patient across verifiable items and used as the primary outcome measure of knowledge accuracy. We used t tests to investigate gender or genotype differences in medical history accuracy. To examine genotype differences, we stratified the sample by SCD genotype: HbSS/Sβ⁰ thalassemia and HbSC/Sβ+ thalassemia [13].

Results

Patient Characteristics

Knowledge Accuracy Among Adolescents with SCD

Seventeen items in 6 PHR domains had the highest number of data points (at least 75% verified), and therefore were the only items that could be analyzed. Analyzed items included information about sickle cell genotype, eye doctor care, comorbid health issues (eg, asthma), allergies, hospitalizations, surgeries, transfusions, acute chest syndrome (ACS) episodes, eye problems, baseline hemoglobin level, and vaccination history as well as adolescents’ knowledge of current medications, including hydroxyurea, penicillin, and opioid pain medications.

Gender was not significantly associated with overall accuracy (P = 0.36). A significant difference was found in sickle genotype such that individuals with HbSC/Sβ+ thalassemia genotype (mean number of items, 8.23; SD = 1.70) were more accurate reporters of their medical history than those with HbSS/Sβ⁰ thalassemia genotype (mean number of items, 7.14; SD = 1.75; t(65) = –2.59, P = 0.01). Specifically, those with HbSS/Sβ⁰ thalassemia genotype were significantly less accurate reporters of vaccination history (meningococcus t(60) = 3.55, P = 0.001; pneumococcus t(60) = 2.46,  P = 0.02; hepatitis t(64) = 2.18, P = 0.03, eye problems t(62) = 3.62; P = 0.001, and surgical history t(62) = 2.14, P = 0.04).

Discussion

In the present study, we utilized the PHR to assess the accuracy of medical history knowledge of adolescents with SCD preparing to transition to adult care. Most adolescents were accurate reporters of important disease-relevant information (eg, genotype, transfusion history, hydroxyurea use), which may be a result of these topics being frequently discussed or recently encountered. For example, 97% of adolescents accurately reported penicillin use which may be related to our program’s emphasis on infection prevention education. However, disease knowledge of immunization history, prior ACS events, and opioid medication use might have been more difficult to recall due to the long interval from their occurrence until the completion of the PHR. Further, frequent changes in opioid medication use may have impacted the accuracy of adolescents’ answers with EMR data.

Individuals with HbSC/Sβ+ thalassemia genotype were more accurate reporters of their medical history, but the magnitude of difference was not large. These individuals tend to have fewer health issues and therefore less health information to recall, leading to higher accuracy. Furthermore, evidence demonstrates that individuals with HbSS/Sβ⁰ thalassemia genotype are at greater risk for cerebrovascular events and subsequent cognitive deficits [14], leading to more memory deficits and difficulty understanding and retaining health information [15]. The results suggest that patient health literacy, or an individual’s capacity to understand basic health information [16], may be a mediating factor in assessing for transition readiness. This is especially important given SCD risk for cognitive deficits [17].

Only 17 PHR items were analyzed due to conservative selection of items. Thus the present findings are not representative of the entire medical history. Additionally, the accuracy of medical history knowledge results may be limited by conservatism with abstracting information from the EMR (PHR information was considered accurate if it matched the information found in their EMR). Finally, we did not systematically assess the feasibility and utility of the PHR; ongoing participant feedback would aid in improving the PHR tool and implementation. It would be important to validate the PHR in a larger sample. However, our study is the first to our knowledge to systematically evaluate medical history knowledge among youth with SCD.

Conclusion and Practice Implications

The present study demonstrates that use of the PHR during regular health maintenance visits can help identify gaps in knowledge among adolescents with SCD who are approaching transfer to adult care. Sufficient knowledge of one’s medical history is an important aspect in transition preparation as it can facilitate the communication of medical information, thereby ensuring continuity of care [18,19]. The PHR could be used to teach medical history knowledge, assess a patient’s level of transition readiness at different time points, and identify areas for further targeted intervention. Knowledge tools, such as the PHR, can be investigated prospectively to assess the association of disease literacy and clinical outcomes, serving as a possible predictive instrument for transition health outcomes.

Corresponding author: Jerlym S. Porter, PhD, MPH, St. Jude Children’s Research Hospital, Dept. of Psychology, 262 Danny Thomas Pl., Mail Stop 740, Memphis, TN 38105, [email protected].

Funding/support: This work was supported in part by HRSA grant 6 U1EMC19331-03-02 (PI: Hankins).

Financial disclosures: None.

Author contributions: conception and design, MJ, AP, KMW, JSH, JSP; analysis and interpretation of data, MSZ, KMR, JSP; drafting of article, MSZ, JSP; critical revision of the article, MSZ, MJ, AP, KMW, JSH, JSP; provision of study materials or patients, MJ, AP; statistical expertise, KMR; obtaining of funding, JSH; collection and assembly of data, MSZ, MJ, AP, KMR, KMW.

From the Departments of Psychology (Ms. Zhao, Drs. Russell, Wesley, and Porter) and Hematology (Mss. Johnson and Pullen, Dr. Hankins), St. Jude Children’s Research Hospital, Memphis, TN.

Abstract

• Background: Children with sickle cell disease (SCD) are surviving into adulthood. Mastery of disease knowledge may facilitate treatment continuity in adult care.
• Objective: To assess the accuracy and extent of medical history knowledge among adolescents with SCD through the use of a personal health record (PHR) form.
• Methods: 68 adolescent patients with SCD (52.9% male; mean age, 16.8 years; 100% African American) completed a PHR listing significant prior medical events (eg, disease complications, diagnostic evaluations, treatments). Responses were compared against participants’ electronic medical record. An agreement percentage was calculated to determine accuracy of knowledge.
• Results: Most adolescents correctly reported their sickle cell genotype (100%), usage of penicillin (97.1%), prior hospitalizations (96.5%), history of prior blood transfusions (93.8%), usage of hydroxyurea (88.2%), and allergies (85.2%). Fewer adolescents accurately reported usage of opioids (52.9%), prior acute chest syndrome events (50.9%), baseline hemoglobin (41.8%), and hepatitis (43.3%), pneumovax (30.2%), and menactra (14.5%) vaccinations.
• Conclusion: Adolescents are aware of most but not all aspects of their medical history. The present findings can inform areas of knowledge deficits. Future targeted interventions for transition education and preparation may be tailored based on individual disease knowledge.

Sickle cell disease (SCD) is a genetic disorder characterized by abnormal sickle hemoglobin resulting in chronic hemolytic anemia and vaso-occlusion [1]. More than 95% of children with SCD in the United States survive into adulthood; however, young adults (YAs) are at risk for mortality shortly after transfer to adult health care [2–5]. Specifically, YAs with SCD (ages 18 to 30) have increased hospital utilization, emergency department visits, and mortality compared to other age-groups [4–7]. During this critical period, transition preparation that includes improving disease literacy and ensuring medical history knowledge may be necessary for optimal outcomes.

In the extant YA literature, significant gaps in medical history knowledge during the transition period were observed in pediatric cancer and inflammatory bowel disease patients [8,9]. YAs often require multidisciplinary management of their chronic disease complications [10]. Therefore, possessing comprehensive knowledge of personal health history may facilitate communication with different adult care providers and promote continuity of care. In the SCD transition literature, transition readiness measures have been developed to assess several aspects of knowledge, including medical and disease knowledge; however, these measures are primarily self-reported perceptions of knowledge and do not evaluate the accuracy of knowledge [11,12]. The current pilot study addresses this gap with the aim of assessing medical history knowledge accuracy in adolescents with SCD.

Methods

Participants

From March 2011 to January 2014, adolescents (aged 15–18 years) with SCD (any genotype) were approached during their regular health maintenance visits by hematology social workers. They were invited to complete the Personal Health Record (PHR) as an implementation effort of transition preparation within our pediatric SCD program.

Personal Health Record

The PHR was developed through literature review and discussions with area adult hematologists. The form was modeled after first visit intake forms used in adult hematology clinics. It was reviewed by the hematology medical team and the institution’s patient education committee. Prior to implementation, the form was piloted to obtain patient feedback on format and content. The PHR consists of 33 questions with 168 possible items/data points covering 12 domains: personal information (eg, contact information, SCD genotype), health provider information, personal health history (ie, health diagnoses), blood transfusion history, sickle cell pain events, hospitalization history in the previous year, diagnostic testing history (eg, laboratory tests), current medications, immunizations, advance directives, resource information (eg, disability benefits), and activities of daily living. Some questions required patients to check “Yes” or “No” (eg, “Have you been hospitalized in the past year? Have you received flu vaccine?”) while some required a written response (eg, “What medicines do you currently take?”).

Adolescents were instructed to complete the PHR independently without the help of their caregivers. After completing the form, the social worker reviewed the answers and/or asked participants’ perspectives about communicating health information to providers. A copy of the completed PHR was provided to the adolescent to promote continued education regarding medical history knowledge. The retrospective review of the PHR answers and participants’ characteristics was approved by the institutional review board with a waiver of consent from participants.

Statistical Methods

PHR answers were compared with each individual’s electronic medical record (EMR) for accuracy of responses. PHR responses were considered accurate only if they matched the information in the EMR. PHR items absent in the EMR were not coded (inability to verify the accuracy of responses) to capture the most accurate depiction of adolescents’ medical history knowledge. Coding was checked by at least 2 coders for response accuracy. Due to lack of EMR information for certain items, we could not verify the accuracy of many PHR items. Therefore, only items with at least 75% of data verified (across all patients who completed the PHR) were included in subsequent analyses.

Using SPSS (version 18), an agreement percentage was calculated for each patient across verifiable items and used as the primary outcome measure of knowledge accuracy. We used t tests to investigate gender or genotype differences in medical history accuracy. To examine genotype differences, we stratified the sample by SCD genotype: HbSS/Sβ⁰ thalassemia and HbSC/Sβ+ thalassemia [13].

Results

Patient Characteristics

Knowledge Accuracy Among Adolescents with SCD

Seventeen items in 6 PHR domains had the highest number of data points (at least 75% verified), and therefore were the only items that could be analyzed. Analyzed items included information about sickle cell genotype, eye doctor care, comorbid health issues (eg, asthma), allergies, hospitalizations, surgeries, transfusions, acute chest syndrome (ACS) episodes, eye problems, baseline hemoglobin level, and vaccination history as well as adolescents’ knowledge of current medications, including hydroxyurea, penicillin, and opioid pain medications.

Gender was not significantly associated with overall accuracy (P = 0.36). A significant difference was found in sickle genotype such that individuals with HbSC/Sβ+ thalassemia genotype (mean number of items, 8.23; SD = 1.70) were more accurate reporters of their medical history than those with HbSS/Sβ⁰ thalassemia genotype (mean number of items, 7.14; SD = 1.75; t(65) = –2.59, P = 0.01). Specifically, those with HbSS/Sβ⁰ thalassemia genotype were significantly less accurate reporters of vaccination history (meningococcus t(60) = 3.55, P = 0.001; pneumococcus t(60) = 2.46,  P = 0.02; hepatitis t(64) = 2.18, P = 0.03, eye problems t(62) = 3.62; P = 0.001, and surgical history t(62) = 2.14, P = 0.04).

Discussion

In the present study, we utilized the PHR to assess the accuracy of medical history knowledge of adolescents with SCD preparing to transition to adult care. Most adolescents were accurate reporters of important disease-relevant information (eg, genotype, transfusion history, hydroxyurea use), which may be a result of these topics being frequently discussed or recently encountered. For example, 97% of adolescents accurately reported penicillin use which may be related to our program’s emphasis on infection prevention education. However, disease knowledge of immunization history, prior ACS events, and opioid medication use might have been more difficult to recall due to the long interval from their occurrence until the completion of the PHR. Further, frequent changes in opioid medication use may have impacted the accuracy of adolescents’ answers with EMR data.

Individuals with HbSC/Sβ+ thalassemia genotype were more accurate reporters of their medical history, but the magnitude of difference was not large. These individuals tend to have fewer health issues and therefore less health information to recall, leading to higher accuracy. Furthermore, evidence demonstrates that individuals with HbSS/Sβ⁰ thalassemia genotype are at greater risk for cerebrovascular events and subsequent cognitive deficits [14], leading to more memory deficits and difficulty understanding and retaining health information [15]. The results suggest that patient health literacy, or an individual’s capacity to understand basic health information [16], may be a mediating factor in assessing for transition readiness. This is especially important given SCD risk for cognitive deficits [17].

Only 17 PHR items were analyzed due to conservative selection of items. Thus the present findings are not representative of the entire medical history. Additionally, the accuracy of medical history knowledge results may be limited by conservatism with abstracting information from the EMR (PHR information was considered accurate if it matched the information found in their EMR). Finally, we did not systematically assess the feasibility and utility of the PHR; ongoing participant feedback would aid in improving the PHR tool and implementation. It would be important to validate the PHR in a larger sample. However, our study is the first to our knowledge to systematically evaluate medical history knowledge among youth with SCD.

Conclusion and Practice Implications

The present study demonstrates that use of the PHR during regular health maintenance visits can help identify gaps in knowledge among adolescents with SCD who are approaching transfer to adult care. Sufficient knowledge of one’s medical history is an important aspect in transition preparation as it can facilitate the communication of medical information, thereby ensuring continuity of care [18,19]. The PHR could be used to teach medical history knowledge, assess a patient’s level of transition readiness at different time points, and identify areas for further targeted intervention. Knowledge tools, such as the PHR, can be investigated prospectively to assess the association of disease literacy and clinical outcomes, serving as a possible predictive instrument for transition health outcomes.

Corresponding author: Jerlym S. Porter, PhD, MPH, St. Jude Children’s Research Hospital, Dept. of Psychology, 262 Danny Thomas Pl., Mail Stop 740, Memphis, TN 38105, [email protected].

Funding/support: This work was supported in part by HRSA grant 6 U1EMC19331-03-02 (PI: Hankins).

Financial disclosures: None.

Author contributions: conception and design, MJ, AP, KMW, JSH, JSP; analysis and interpretation of data, MSZ, KMR, JSP; drafting of article, MSZ, JSP; critical revision of the article, MSZ, MJ, AP, KMW, JSH, JSP; provision of study materials or patients, MJ, AP; statistical expertise, KMR; obtaining of funding, JSH; collection and assembly of data, MSZ, MJ, AP, KMR, KMW.

From the Departments of Psychology (Ms. Zhao, Drs. Russell, Wesley, and Porter) and Hematology (Mss. Johnson and Pullen, Dr. Hankins), St. Jude Children’s Research Hospital, Memphis, TN.

Abstract

• Background: Children with sickle cell disease (SCD) are surviving into adulthood. Mastery of disease knowledge may facilitate treatment continuity in adult care.
• Objective: To assess the accuracy and extent of medical history knowledge among adolescents with SCD through the use of a personal health record (PHR) form.
• Methods: 68 adolescent patients with SCD (52.9% male; mean age, 16.8 years; 100% African American) completed a PHR listing significant prior medical events (eg, disease complications, diagnostic evaluations, treatments). Responses were compared against participants’ electronic medical record. An agreement percentage was calculated to determine accuracy of knowledge.
• Results: Most adolescents correctly reported their sickle cell genotype (100%), usage of penicillin (97.1%), prior hospitalizations (96.5%), history of prior blood transfusions (93.8%), usage of hydroxyurea (88.2%), and allergies (85.2%). Fewer adolescents accurately reported usage of opioids (52.9%), prior acute chest syndrome events (50.9%), baseline hemoglobin (41.8%), and hepatitis (43.3%), pneumovax (30.2%), and menactra (14.5%) vaccinations.
• Conclusion: Adolescents are aware of most but not all aspects of their medical history. The present findings can inform areas of knowledge deficits. Future targeted interventions for transition education and preparation may be tailored based on individual disease knowledge.

Sickle cell disease (SCD) is a genetic disorder characterized by abnormal sickle hemoglobin resulting in chronic hemolytic anemia and vaso-occlusion [1]. More than 95% of children with SCD in the United States survive into adulthood; however, young adults (YAs) are at risk for mortality shortly after transfer to adult health care [2–5]. Specifically, YAs with SCD (ages 18 to 30) have increased hospital utilization, emergency department visits, and mortality compared to other age-groups [4–7]. During this critical period, transition preparation that includes improving disease literacy and ensuring medical history knowledge may be necessary for optimal outcomes.

In the extant YA literature, significant gaps in medical history knowledge during the transition period were observed in pediatric cancer and inflammatory bowel disease patients [8,9]. YAs often require multidisciplinary management of their chronic disease complications [10]. Therefore, possessing comprehensive knowledge of personal health history may facilitate communication with different adult care providers and promote continuity of care. In the SCD transition literature, transition readiness measures have been developed to assess several aspects of knowledge, including medical and disease knowledge; however, these measures are primarily self-reported perceptions of knowledge and do not evaluate the accuracy of knowledge [11,12]. The current pilot study addresses this gap with the aim of assessing medical history knowledge accuracy in adolescents with SCD.

Methods

Participants

From March 2011 to January 2014, adolescents (aged 15–18 years) with SCD (any genotype) were approached during their regular health maintenance visits by hematology social workers. They were invited to complete the Personal Health Record (PHR) as an implementation effort of transition preparation within our pediatric SCD program.

Personal Health Record

The PHR was developed through literature review and discussions with area adult hematologists. The form was modeled after first visit intake forms used in adult hematology clinics. It was reviewed by the hematology medical team and the institution’s patient education committee. Prior to implementation, the form was piloted to obtain patient feedback on format and content. The PHR consists of 33 questions with 168 possible items/data points covering 12 domains: personal information (eg, contact information, SCD genotype), health provider information, personal health history (ie, health diagnoses), blood transfusion history, sickle cell pain events, hospitalization history in the previous year, diagnostic testing history (eg, laboratory tests), current medications, immunizations, advance directives, resource information (eg, disability benefits), and activities of daily living. Some questions required patients to check “Yes” or “No” (eg, “Have you been hospitalized in the past year? Have you received flu vaccine?”) while some required a written response (eg, “What medicines do you currently take?”).

Adolescents were instructed to complete the PHR independently without the help of their caregivers. After completing the form, the social worker reviewed the answers and/or asked participants’ perspectives about communicating health information to providers. A copy of the completed PHR was provided to the adolescent to promote continued education regarding medical history knowledge. The retrospective review of the PHR answers and participants’ characteristics was approved by the institutional review board with a waiver of consent from participants.

Statistical Methods

PHR answers were compared with each individual’s electronic medical record (EMR) for accuracy of responses. PHR responses were considered accurate only if they matched the information in the EMR. PHR items absent in the EMR were not coded (inability to verify the accuracy of responses) to capture the most accurate depiction of adolescents’ medical history knowledge. Coding was checked by at least 2 coders for response accuracy. Due to lack of EMR information for certain items, we could not verify the accuracy of many PHR items. Therefore, only items with at least 75% of data verified (across all patients who completed the PHR) were included in subsequent analyses.

Using SPSS (version 18), an agreement percentage was calculated for each patient across verifiable items and used as the primary outcome measure of knowledge accuracy. We used t tests to investigate gender or genotype differences in medical history accuracy. To examine genotype differences, we stratified the sample by SCD genotype: HbSS/Sβ⁰ thalassemia and HbSC/Sβ+ thalassemia [13].

Results

Patient Characteristics

Knowledge Accuracy Among Adolescents with SCD

Seventeen items in 6 PHR domains had the highest number of data points (at least 75% verified), and therefore were the only items that could be analyzed. Analyzed items included information about sickle cell genotype, eye doctor care, comorbid health issues (eg, asthma), allergies, hospitalizations, surgeries, transfusions, acute chest syndrome (ACS) episodes, eye problems, baseline hemoglobin level, and vaccination history as well as adolescents’ knowledge of current medications, including hydroxyurea, penicillin, and opioid pain medications.

Gender was not significantly associated with overall accuracy (P = 0.36). A significant difference was found in sickle genotype such that individuals with HbSC/Sβ+ thalassemia genotype (mean number of items, 8.23; SD = 1.70) were more accurate reporters of their medical history than those with HbSS/Sβ⁰ thalassemia genotype (mean number of items, 7.14; SD = 1.75; t(65) = –2.59, P = 0.01). Specifically, those with HbSS/Sβ⁰ thalassemia genotype were significantly less accurate reporters of vaccination history (meningococcus t(60) = 3.55, P = 0.001; pneumococcus t(60) = 2.46,  P = 0.02; hepatitis t(64) = 2.18, P = 0.03, eye problems t(62) = 3.62; P = 0.001, and surgical history t(62) = 2.14, P = 0.04).

Discussion

In the present study, we utilized the PHR to assess the accuracy of medical history knowledge of adolescents with SCD preparing to transition to adult care. Most adolescents were accurate reporters of important disease-relevant information (eg, genotype, transfusion history, hydroxyurea use), which may be a result of these topics being frequently discussed or recently encountered. For example, 97% of adolescents accurately reported penicillin use which may be related to our program’s emphasis on infection prevention education. However, disease knowledge of immunization history, prior ACS events, and opioid medication use might have been more difficult to recall due to the long interval from their occurrence until the completion of the PHR. Further, frequent changes in opioid medication use may have impacted the accuracy of adolescents’ answers with EMR data.

Individuals with HbSC/Sβ+ thalassemia genotype were more accurate reporters of their medical history, but the magnitude of difference was not large. These individuals tend to have fewer health issues and therefore less health information to recall, leading to higher accuracy. Furthermore, evidence demonstrates that individuals with HbSS/Sβ⁰ thalassemia genotype are at greater risk for cerebrovascular events and subsequent cognitive deficits [14], leading to more memory deficits and difficulty understanding and retaining health information [15]. The results suggest that patient health literacy, or an individual’s capacity to understand basic health information [16], may be a mediating factor in assessing for transition readiness. This is especially important given SCD risk for cognitive deficits [17].

Only 17 PHR items were analyzed due to conservative selection of items. Thus the present findings are not representative of the entire medical history. Additionally, the accuracy of medical history knowledge results may be limited by conservatism with abstracting information from the EMR (PHR information was considered accurate if it matched the information found in their EMR). Finally, we did not systematically assess the feasibility and utility of the PHR; ongoing participant feedback would aid in improving the PHR tool and implementation. It would be important to validate the PHR in a larger sample. However, our study is the first to our knowledge to systematically evaluate medical history knowledge among youth with SCD.

Conclusion and Practice Implications

The present study demonstrates that use of the PHR during regular health maintenance visits can help identify gaps in knowledge among adolescents with SCD who are approaching transfer to adult care. Sufficient knowledge of one’s medical history is an important aspect in transition preparation as it can facilitate the communication of medical information, thereby ensuring continuity of care [18,19]. The PHR could be used to teach medical history knowledge, assess a patient’s level of transition readiness at different time points, and identify areas for further targeted intervention. Knowledge tools, such as the PHR, can be investigated prospectively to assess the association of disease literacy and clinical outcomes, serving as a possible predictive instrument for transition health outcomes.

Corresponding author: Jerlym S. Porter, PhD, MPH, St. Jude Children’s Research Hospital, Dept. of Psychology, 262 Danny Thomas Pl., Mail Stop 740, Memphis, TN 38105, [email protected].

Funding/support: This work was supported in part by HRSA grant 6 U1EMC19331-03-02 (PI: Hankins).

Financial disclosures: None.

Author contributions: conception and design, MJ, AP, KMW, JSH, JSP; analysis and interpretation of data, MSZ, KMR, JSP; drafting of article, MSZ, JSP; critical revision of the article, MSZ, MJ, AP, KMW, JSH, JSP; provision of study materials or patients, MJ, AP; statistical expertise, KMR; obtaining of funding, JSH; collection and assembly of data, MSZ, MJ, AP, KMR, KMW.

Study Overview

Objective. To compare several behavioral strategies for weight gain prevention in young adults.

Study design. Randomized clinical trial.

Setting and participants. The study took place at 2 U.S. academic centers between 2010 and 2016. Participants were recruited using email and postal mailings if they were 18–35 years old, had a body mass index (BMI) between 21 and 30.9 (ie, they ranged from normal body weight to class I obesity), spoke English, had internet access, and did not have contraindications to participating in a behavioral weight management intervention (eg, eating disorders). Once recruited, participants were block randomized, stratified by site, sex, and ethnic group, in to 1 of 3 study arms. The control arm of the study consisted of a single in-person meeting where behavioral strategies to prevent weight gain were discussed, as well as quarterly newsletters and personalized reports on interim weight data during follow-up.

Intervention. There were 2 intervention arms in the study. Both intervention groups had 10 in-person group-based visits over the initial 4 months of the intervention, at which strategies to prevent weight gain were discussed. Additionally they received annual invitations to participate in online refresher courses and the same newsletter frequency and content as the control group. Advice to the 2 intervention groups differed, however. Those in the “small changes” group were advised to decrease caloric intake by about 100 kcal per day in order to prevent weight gain. Additionally they were given pedometers, with a goal of increasing their daily step counts by about 2000. In the “large changes” group, participants were given lower calorie targets and more aggressive physical activity goals, with a goal of producing weight loss over the first 4 months of follow-up (2.3 kg for those with normal baseline BMI, and 4.5 kg if overweight or obese at baseline). Participants in all groups were encouraged to engage in self-monitoring behaviors such as daily weighing, and to report these weights to study staff by email, text, or on the web. Aside from pre-specified study follow-up assessments, most follow-up beyond the initial 4 month “small” or “large” changes phase was done using email or web-based intervention.

Main outcome measures. All participants were scheduled for follow-up assessments at 4 months, 1 year, and 2 years, with some early participants having additional follow-ups at 3 and 4 years. The primary outcome of interest was change in weight from baseline through follow-up, with additional outcome measures including the proportion in each group who gained at least 0.45 kg, or developed obesity. Additionally, the investigators did a thorough evaluation of intervention implementation and delivery. Weight change was modeled using mixed effects linear models, adjusting for clinic site. They corrected for multiple measures using Bonferroni adjustment to minimize the risk of type I error and used multiple imputation to examine the impact of missing data on their results. Pre-specified subgroup comparisons between several groups of patients were conducted—those in the normal weight vs. overweight category at baseline, those younger vs. older than age 25 at baseline, and men vs. women.

Results. 599 participants were randomized to the control (n = 202), small changes (n = 200), or large changes groups (n = 197), with no significant differences between groups in terms of measured baseline characteristics. The majority of participants were women (78%) and non-Hispanic white (73%). Mean (SD) baseline age was 28.2 (4.4) years and BMI was 25.4 (2.6) kg/m². The group as a whole was highly educated—between 77% and 82% had college degrees. The series of 10 intervention sessions in the first 4 months was very well-attended (87% attendance on average for large changes group, 86% for small changes group), and by 4 months of follow-up, a majority of participants in both intervention groups endorsed the behavior of daily self-weighing (75% in large changes, 72% in small changes).

Both intervention groups had statistically significant weight losses compared to control (average weight change in control +0.3 kg, in small change –0.6 kg, and in large change –2.4 kg, over an average of 3 years), with large change participants also having significantly greater average weight loss in follow-up than small change participants. Significantly fewer participants in the intervention groups went on to develop obesity than in the control group (16.9% incidence in control, vs. 7.9% incidence in small changes [P = 0.002] and 8.6% in large changes [P = 0.02]). Importantly, the trajectories of weight gain (or regain) after the initial 4-month intervention differed between the small and large change groups, with small change participants experiencing a more gradual rate of gain throughout follow-up, versus a steeper rate of gain in the large changes group, such that the groups were at very similar weights by the final time point. The investigators did not observe any differences in effect between subgroups according to participant baseline BMI, sex, age, or race.

Conclusion. The authors conclude that these scalable small- and large-change interventions reduced longer-term weight gain and even promoted weight loss in a group of young adults, with the large-change intervention having a greater impact on weight than the small-change intervention.

Commentary

Treatment of obesity is difficult, leading to frustration for many patients and clinicians. Although it is often possible to help patients lose weight with tools such as low-calorie diets and increased physical activity, the long-term maintenance of weight loss is quite challenging. There is a growing awareness that the difficulty in maintaining weight loss has strong physiologic underpinnings. The human body has complex energy regulatory systems that may oppose weight loss by lowering metabolic rate, increasing hunger cues, and limiting satiety cues, when faced with energy restriction or weight loss [1,2].

In order to decrease the number of patients who ultimately require treatment for obesity, an alternative approach may be to try to prevent weight gain in the first place. Young adults in the U.S. tend to gain weight steadily over time, yet this insidious pattern is unlikely to be addressed by physicians [3]. Given that gradual weight gain seems to be the norm for most young adults, it may be beneficial for primary care providers to advise all young adult patients to make small behavioral changes in order to prevent the onset of overweight or obesity. Preventing weight gain is an attractive approach for broad application because it may require lower intensity programs, and less behavioral commitment from patients, compared to what is required for weight loss [4].

In this randomized trial, Wing et al investigated several relatively low-intensity approaches for weight gain prevention. Strengths of the study include aspects of the design and analysis, including its randomized nature, the relatively long follow-up period, the use of multiple imputation to address missing data, and the use of statistical methods to account for the large number of comparisons made between groups over time (Bonferroni correction). More importantly, however, this study represents an important innovation in how physicians might think about obesity, with a shift toward prevention rather than treatment. Historically, many obesity prevention efforts have fallen in the domain of public health or population-level interventions, and it may be the case that physicians have felt they did not really have a role in prevention. On the other hand, doctors who have engaged in obesity treatment—trying to help patients lose weight—may have felt that they lacked the resources or training needed to implement successful programs to promote long-term weight loss. By testing several lower-intensity strategies for weight gain prevention, this study sheds light on what could possibly be a new role for primary care providers or health care systems who care for otherwise healthy young adults. As the authors point out, the methods they employed could also be easily scaled or disseminated using public health approaches and community organizations.

In addition to addressing an important topic, this study relied on intervention methods that would be relatively easy to replicate in clinical practice or in community settings. Aside from the initial 4-month intervention, which involved 10 face-to-face group sessions (which were very well attended by participants), the remainder of the ~3 year follow-up consisted mostly of contact that took place electronically using email and/or text messaging. These modes of communication align well with the move toward electronic health records (eg, e-visits) and are probably ideally suited for young adults, who as a group rely heavily on these methods of communication.

The study has several limitations, most of which are addressed by the authors in the discussion section of the paper. As with most studies of behavioral weight interventions, the majority of participants in this study were women, with relatively few racial and ethnic minorities. Furthermore this was a highly educated group of participants and it is unclear whether these results would generalize to a more diverse clinical population with fewer resources or lower health literacy. Given that the control arm of the study experienced less weight gain over time than would be expected based on population averages, it could be that the participants in this study were a select group of individuals who were more motivated around preventing long-term health problems than a general clinical population. One additional point of possible concern is that, while participants in the “large changes” group did, as per the design, lose weight at the beginning of the trial, they also went on to regain much of that weight and experienced a steeper trajectory of overall gain during follow-up compared to the “small changes” group, so that the 2 intervention groups were not statistically different from each other in terms of overall weight change from baseline by 2 years. Therefore, whether the “large changes” approach is truly more beneficial for long-term obesity prevention than the more modest “small changes” approach is not entirely clear from this study.

Applications for Clinical Practice

The identification of young adults who are gaining weight, but who are not yet obese, represents an opportunity for providers and health care systems. Efforts to promote modest dietary and physical activity changes in this population may prevent obesity, and may be achievable even in busy clinical practice settings. Whether weight-gain prevention programs should include an attempt to first foster a small amount of weight loss as a “buffer” against later gains is still not entirely clear.

—Kristina Lewis, MD, MPH

Study Overview

Objective. To compare several behavioral strategies for weight gain prevention in young adults.

Study design. Randomized clinical trial.

Setting and participants. The study took place at 2 U.S. academic centers between 2010 and 2016. Participants were recruited using email and postal mailings if they were 18–35 years old, had a body mass index (BMI) between 21 and 30.9 (ie, they ranged from normal body weight to class I obesity), spoke English, had internet access, and did not have contraindications to participating in a behavioral weight management intervention (eg, eating disorders). Once recruited, participants were block randomized, stratified by site, sex, and ethnic group, in to 1 of 3 study arms. The control arm of the study consisted of a single in-person meeting where behavioral strategies to prevent weight gain were discussed, as well as quarterly newsletters and personalized reports on interim weight data during follow-up.

Intervention. There were 2 intervention arms in the study. Both intervention groups had 10 in-person group-based visits over the initial 4 months of the intervention, at which strategies to prevent weight gain were discussed. Additionally they received annual invitations to participate in online refresher courses and the same newsletter frequency and content as the control group. Advice to the 2 intervention groups differed, however. Those in the “small changes” group were advised to decrease caloric intake by about 100 kcal per day in order to prevent weight gain. Additionally they were given pedometers, with a goal of increasing their daily step counts by about 2000. In the “large changes” group, participants were given lower calorie targets and more aggressive physical activity goals, with a goal of producing weight loss over the first 4 months of follow-up (2.3 kg for those with normal baseline BMI, and 4.5 kg if overweight or obese at baseline). Participants in all groups were encouraged to engage in self-monitoring behaviors such as daily weighing, and to report these weights to study staff by email, text, or on the web. Aside from pre-specified study follow-up assessments, most follow-up beyond the initial 4 month “small” or “large” changes phase was done using email or web-based intervention.

Main outcome measures. All participants were scheduled for follow-up assessments at 4 months, 1 year, and 2 years, with some early participants having additional follow-ups at 3 and 4 years. The primary outcome of interest was change in weight from baseline through follow-up, with additional outcome measures including the proportion in each group who gained at least 0.45 kg, or developed obesity. Additionally, the investigators did a thorough evaluation of intervention implementation and delivery. Weight change was modeled using mixed effects linear models, adjusting for clinic site. They corrected for multiple measures using Bonferroni adjustment to minimize the risk of type I error and used multiple imputation to examine the impact of missing data on their results. Pre-specified subgroup comparisons between several groups of patients were conducted—those in the normal weight vs. overweight category at baseline, those younger vs. older than age 25 at baseline, and men vs. women.

Results. 599 participants were randomized to the control (n = 202), small changes (n = 200), or large changes groups (n = 197), with no significant differences between groups in terms of measured baseline characteristics. The majority of participants were women (78%) and non-Hispanic white (73%). Mean (SD) baseline age was 28.2 (4.4) years and BMI was 25.4 (2.6) kg/m². The group as a whole was highly educated—between 77% and 82% had college degrees. The series of 10 intervention sessions in the first 4 months was very well-attended (87% attendance on average for large changes group, 86% for small changes group), and by 4 months of follow-up, a majority of participants in both intervention groups endorsed the behavior of daily self-weighing (75% in large changes, 72% in small changes).

Both intervention groups had statistically significant weight losses compared to control (average weight change in control +0.3 kg, in small change –0.6 kg, and in large change –2.4 kg, over an average of 3 years), with large change participants also having significantly greater average weight loss in follow-up than small change participants. Significantly fewer participants in the intervention groups went on to develop obesity than in the control group (16.9% incidence in control, vs. 7.9% incidence in small changes [P = 0.002] and 8.6% in large changes [P = 0.02]). Importantly, the trajectories of weight gain (or regain) after the initial 4-month intervention differed between the small and large change groups, with small change participants experiencing a more gradual rate of gain throughout follow-up, versus a steeper rate of gain in the large changes group, such that the groups were at very similar weights by the final time point. The investigators did not observe any differences in effect between subgroups according to participant baseline BMI, sex, age, or race.

Conclusion. The authors conclude that these scalable small- and large-change interventions reduced longer-term weight gain and even promoted weight loss in a group of young adults, with the large-change intervention having a greater impact on weight than the small-change intervention.

Commentary

Treatment of obesity is difficult, leading to frustration for many patients and clinicians. Although it is often possible to help patients lose weight with tools such as low-calorie diets and increased physical activity, the long-term maintenance of weight loss is quite challenging. There is a growing awareness that the difficulty in maintaining weight loss has strong physiologic underpinnings. The human body has complex energy regulatory systems that may oppose weight loss by lowering metabolic rate, increasing hunger cues, and limiting satiety cues, when faced with energy restriction or weight loss [1,2].

In order to decrease the number of patients who ultimately require treatment for obesity, an alternative approach may be to try to prevent weight gain in the first place. Young adults in the U.S. tend to gain weight steadily over time, yet this insidious pattern is unlikely to be addressed by physicians [3]. Given that gradual weight gain seems to be the norm for most young adults, it may be beneficial for primary care providers to advise all young adult patients to make small behavioral changes in order to prevent the onset of overweight or obesity. Preventing weight gain is an attractive approach for broad application because it may require lower intensity programs, and less behavioral commitment from patients, compared to what is required for weight loss [4].

In this randomized trial, Wing et al investigated several relatively low-intensity approaches for weight gain prevention. Strengths of the study include aspects of the design and analysis, including its randomized nature, the relatively long follow-up period, the use of multiple imputation to address missing data, and the use of statistical methods to account for the large number of comparisons made between groups over time (Bonferroni correction). More importantly, however, this study represents an important innovation in how physicians might think about obesity, with a shift toward prevention rather than treatment. Historically, many obesity prevention efforts have fallen in the domain of public health or population-level interventions, and it may be the case that physicians have felt they did not really have a role in prevention. On the other hand, doctors who have engaged in obesity treatment—trying to help patients lose weight—may have felt that they lacked the resources or training needed to implement successful programs to promote long-term weight loss. By testing several lower-intensity strategies for weight gain prevention, this study sheds light on what could possibly be a new role for primary care providers or health care systems who care for otherwise healthy young adults. As the authors point out, the methods they employed could also be easily scaled or disseminated using public health approaches and community organizations.

In addition to addressing an important topic, this study relied on intervention methods that would be relatively easy to replicate in clinical practice or in community settings. Aside from the initial 4-month intervention, which involved 10 face-to-face group sessions (which were very well attended by participants), the remainder of the ~3 year follow-up consisted mostly of contact that took place electronically using email and/or text messaging. These modes of communication align well with the move toward electronic health records (eg, e-visits) and are probably ideally suited for young adults, who as a group rely heavily on these methods of communication.

The study has several limitations, most of which are addressed by the authors in the discussion section of the paper. As with most studies of behavioral weight interventions, the majority of participants in this study were women, with relatively few racial and ethnic minorities. Furthermore this was a highly educated group of participants and it is unclear whether these results would generalize to a more diverse clinical population with fewer resources or lower health literacy. Given that the control arm of the study experienced less weight gain over time than would be expected based on population averages, it could be that the participants in this study were a select group of individuals who were more motivated around preventing long-term health problems than a general clinical population. One additional point of possible concern is that, while participants in the “large changes” group did, as per the design, lose weight at the beginning of the trial, they also went on to regain much of that weight and experienced a steeper trajectory of overall gain during follow-up compared to the “small changes” group, so that the 2 intervention groups were not statistically different from each other in terms of overall weight change from baseline by 2 years. Therefore, whether the “large changes” approach is truly more beneficial for long-term obesity prevention than the more modest “small changes” approach is not entirely clear from this study.

Applications for Clinical Practice

The identification of young adults who are gaining weight, but who are not yet obese, represents an opportunity for providers and health care systems. Efforts to promote modest dietary and physical activity changes in this population may prevent obesity, and may be achievable even in busy clinical practice settings. Whether weight-gain prevention programs should include an attempt to first foster a small amount of weight loss as a “buffer” against later gains is still not entirely clear.

—Kristina Lewis, MD, MPH

Study Overview

Objective. To compare several behavioral strategies for weight gain prevention in young adults.

Study design. Randomized clinical trial.

Setting and participants. The study took place at 2 U.S. academic centers between 2010 and 2016. Participants were recruited using email and postal mailings if they were 18–35 years old, had a body mass index (BMI) between 21 and 30.9 (ie, they ranged from normal body weight to class I obesity), spoke English, had internet access, and did not have contraindications to participating in a behavioral weight management intervention (eg, eating disorders). Once recruited, participants were block randomized, stratified by site, sex, and ethnic group, in to 1 of 3 study arms. The control arm of the study consisted of a single in-person meeting where behavioral strategies to prevent weight gain were discussed, as well as quarterly newsletters and personalized reports on interim weight data during follow-up.

Intervention. There were 2 intervention arms in the study. Both intervention groups had 10 in-person group-based visits over the initial 4 months of the intervention, at which strategies to prevent weight gain were discussed. Additionally they received annual invitations to participate in online refresher courses and the same newsletter frequency and content as the control group. Advice to the 2 intervention groups differed, however. Those in the “small changes” group were advised to decrease caloric intake by about 100 kcal per day in order to prevent weight gain. Additionally they were given pedometers, with a goal of increasing their daily step counts by about 2000. In the “large changes” group, participants were given lower calorie targets and more aggressive physical activity goals, with a goal of producing weight loss over the first 4 months of follow-up (2.3 kg for those with normal baseline BMI, and 4.5 kg if overweight or obese at baseline). Participants in all groups were encouraged to engage in self-monitoring behaviors such as daily weighing, and to report these weights to study staff by email, text, or on the web. Aside from pre-specified study follow-up assessments, most follow-up beyond the initial 4 month “small” or “large” changes phase was done using email or web-based intervention.

Main outcome measures. All participants were scheduled for follow-up assessments at 4 months, 1 year, and 2 years, with some early participants having additional follow-ups at 3 and 4 years. The primary outcome of interest was change in weight from baseline through follow-up, with additional outcome measures including the proportion in each group who gained at least 0.45 kg, or developed obesity. Additionally, the investigators did a thorough evaluation of intervention implementation and delivery. Weight change was modeled using mixed effects linear models, adjusting for clinic site. They corrected for multiple measures using Bonferroni adjustment to minimize the risk of type I error and used multiple imputation to examine the impact of missing data on their results. Pre-specified subgroup comparisons between several groups of patients were conducted—those in the normal weight vs. overweight category at baseline, those younger vs. older than age 25 at baseline, and men vs. women.

Results. 599 participants were randomized to the control (n = 202), small changes (n = 200), or large changes groups (n = 197), with no significant differences between groups in terms of measured baseline characteristics. The majority of participants were women (78%) and non-Hispanic white (73%). Mean (SD) baseline age was 28.2 (4.4) years and BMI was 25.4 (2.6) kg/m². The group as a whole was highly educated—between 77% and 82% had college degrees. The series of 10 intervention sessions in the first 4 months was very well-attended (87% attendance on average for large changes group, 86% for small changes group), and by 4 months of follow-up, a majority of participants in both intervention groups endorsed the behavior of daily self-weighing (75% in large changes, 72% in small changes).

Both intervention groups had statistically significant weight losses compared to control (average weight change in control +0.3 kg, in small change –0.6 kg, and in large change –2.4 kg, over an average of 3 years), with large change participants also having significantly greater average weight loss in follow-up than small change participants. Significantly fewer participants in the intervention groups went on to develop obesity than in the control group (16.9% incidence in control, vs. 7.9% incidence in small changes [P = 0.002] and 8.6% in large changes [P = 0.02]). Importantly, the trajectories of weight gain (or regain) after the initial 4-month intervention differed between the small and large change groups, with small change participants experiencing a more gradual rate of gain throughout follow-up, versus a steeper rate of gain in the large changes group, such that the groups were at very similar weights by the final time point. The investigators did not observe any differences in effect between subgroups according to participant baseline BMI, sex, age, or race.

Conclusion. The authors conclude that these scalable small- and large-change interventions reduced longer-term weight gain and even promoted weight loss in a group of young adults, with the large-change intervention having a greater impact on weight than the small-change intervention.

Commentary

Treatment of obesity is difficult, leading to frustration for many patients and clinicians. Although it is often possible to help patients lose weight with tools such as low-calorie diets and increased physical activity, the long-term maintenance of weight loss is quite challenging. There is a growing awareness that the difficulty in maintaining weight loss has strong physiologic underpinnings. The human body has complex energy regulatory systems that may oppose weight loss by lowering metabolic rate, increasing hunger cues, and limiting satiety cues, when faced with energy restriction or weight loss [1,2].

In order to decrease the number of patients who ultimately require treatment for obesity, an alternative approach may be to try to prevent weight gain in the first place. Young adults in the U.S. tend to gain weight steadily over time, yet this insidious pattern is unlikely to be addressed by physicians [3]. Given that gradual weight gain seems to be the norm for most young adults, it may be beneficial for primary care providers to advise all young adult patients to make small behavioral changes in order to prevent the onset of overweight or obesity. Preventing weight gain is an attractive approach for broad application because it may require lower intensity programs, and less behavioral commitment from patients, compared to what is required for weight loss [4].

In this randomized trial, Wing et al investigated several relatively low-intensity approaches for weight gain prevention. Strengths of the study include aspects of the design and analysis, including its randomized nature, the relatively long follow-up period, the use of multiple imputation to address missing data, and the use of statistical methods to account for the large number of comparisons made between groups over time (Bonferroni correction). More importantly, however, this study represents an important innovation in how physicians might think about obesity, with a shift toward prevention rather than treatment. Historically, many obesity prevention efforts have fallen in the domain of public health or population-level interventions, and it may be the case that physicians have felt they did not really have a role in prevention. On the other hand, doctors who have engaged in obesity treatment—trying to help patients lose weight—may have felt that they lacked the resources or training needed to implement successful programs to promote long-term weight loss. By testing several lower-intensity strategies for weight gain prevention, this study sheds light on what could possibly be a new role for primary care providers or health care systems who care for otherwise healthy young adults. As the authors point out, the methods they employed could also be easily scaled or disseminated using public health approaches and community organizations.

In addition to addressing an important topic, this study relied on intervention methods that would be relatively easy to replicate in clinical practice or in community settings. Aside from the initial 4-month intervention, which involved 10 face-to-face group sessions (which were very well attended by participants), the remainder of the ~3 year follow-up consisted mostly of contact that took place electronically using email and/or text messaging. These modes of communication align well with the move toward electronic health records (eg, e-visits) and are probably ideally suited for young adults, who as a group rely heavily on these methods of communication.

The study has several limitations, most of which are addressed by the authors in the discussion section of the paper. As with most studies of behavioral weight interventions, the majority of participants in this study were women, with relatively few racial and ethnic minorities. Furthermore this was a highly educated group of participants and it is unclear whether these results would generalize to a more diverse clinical population with fewer resources or lower health literacy. Given that the control arm of the study experienced less weight gain over time than would be expected based on population averages, it could be that the participants in this study were a select group of individuals who were more motivated around preventing long-term health problems than a general clinical population. One additional point of possible concern is that, while participants in the “large changes” group did, as per the design, lose weight at the beginning of the trial, they also went on to regain much of that weight and experienced a steeper trajectory of overall gain during follow-up compared to the “small changes” group, so that the 2 intervention groups were not statistically different from each other in terms of overall weight change from baseline by 2 years. Therefore, whether the “large changes” approach is truly more beneficial for long-term obesity prevention than the more modest “small changes” approach is not entirely clear from this study.

Applications for Clinical Practice

The identification of young adults who are gaining weight, but who are not yet obese, represents an opportunity for providers and health care systems. Efforts to promote modest dietary and physical activity changes in this population may prevent obesity, and may be achievable even in busy clinical practice settings. Whether weight-gain prevention programs should include an attempt to first foster a small amount of weight loss as a “buffer” against later gains is still not entirely clear.

—Kristina Lewis, MD, MPH

ATLANTA – A new scale for predicting complicated alcohol withdrawal syndrome in hospitalized medically ill patients had high sensitivity and specificity in a prospective validation study.

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) can help clinicians identify those at risk for complicated alcohol withdrawal syndrome (AWS), and either prevent or treat complicated AWS in a timely manner, Dr. José R. Maldonado of Stanford (Calif.) University said at the annual meeting of the American Psychiatric Association.

In 403 subjects hospitalized to general medicine and surgery units over a 12-month period, the PAWSS – along with the Clinical Institute Withdrawal Assessment–alcohol revised (CIWA-Ar) and clinical monitoring – was administered daily. Using a cutoff score of 4 on the 0-10 point PAWSS, the tool had sensitivity and positive predictive value of 93.1%, and specificity and negative predictive value of 99.5% for identifying complicated AWS, Dr. Maldonado said, noting that the tool also had excellent inter-rater reliability.

The findings are important because the prevalence of alcohol use disorders among hospitalized medically ill patients exceeds 40%, he said, noting that medically ill patients with AWS tend to have a significant number of complications, which makes them “not only very difficult to treat but also very high risk.”

Importantly, seizures – commonly known as “rum fits,” which occur in 5%-15% of cases – happen very early on in the course of AWS. This is a concern, because it has implications for prescribing, Dr. Maldonado said.

Another concern, and “probably the most dreadful of them all,” is delirium tremens (DTs), a severe symptom of alcohol withdrawal that occurs in about 10% of patients with AWS.

The overall mortality associated with DTs is 1% in non–medically ill patients, but in the medically ill, this figure increases to 20% because of the frequency of comorbidities, such as heart disease and diabetes in this population. Also, DTs tend to occur a few days into withdrawal, peaking on day 5, which could be problematic; a trauma patient who is intubated in the operating room, for example, still could go through withdrawal a few days later, as most medications being used in that patient are not going to prevent it, he explained.

Previously, no tool was available to predict complicated AWS to prevent seizures and DTs. Existing tools such as the CIWA and AWS scale assess AWS severity but do not predict who will withdraw, he noted, explaining that by the time the CIWA scale is positive, the patient already is in withdrawal.

One option is to treat everyone with benzodiazepines or other drugs that facilitate GABA (gamma-aminobutyric acid) transmission in patients at risk of AWS, but this unnecessarily puts 80% of patients at risk of numerous side effects, including excessive sedation, falls, respiratory depression, and medication-induced delirium.

A benzodiazepine-sparing protocol, which involved the use of alpha-2 agonists and anticonvulsants instead of benzodiazepines, was being studied at Stanford, comparing outcomes in patients treated with and without benzodiazepines.

“But before we started to use alpha-2 agonists and anticonvulsants ... we wanted to make sure that we were actually treating the population that really needs it. That was the main motivation for creating this tool,” he said. “The other thing is we wanted to make sure that we don’t scare people away from treating patients with potential alcohol withdrawal, because the consequences of withdrawal are dreadful, not only immediately but also into the future.”

Every time someone goes through withdrawal, it is more severe than before, and it lowers the threshold for DTs, he added.

An extensive literature review for anything associated with the various phases of alcohol withdrawal was performed to help develop the PAWSS, which includes 10 highly predictive questions for any patients who first indicate that they have had alcohol in the prior 30 days, or who is admitted with a positive blood alcohol level test.

A pilot study involving 70 patients yielded a sensitivity and specificity of 100% each, leading to the larger study of hospitalized patients, which was published last year in Alcohol and Alcoholism (2015 May 21. doi: 10.1093/alcalc/agv043).

A check of admission notes would have increased the ultimate sensitivity of the scale to 100%, as false answers provided on the scale were easily identified. Blood alcohol level testing also would help.

But PAWSS is meant to provide timely information, which is important in patients at risk, and another purpose for developing PAWSS was to provide an affordable tool that can be used anywhere, including rural community hospitals or clinics where other tests might not be available, Dr. Maldonado said.

Currently, he and his colleagues are evaluating whether all 10 items on the scale are needed to make a diagnosis, or whether a shorter version would be equally useful.

“The incidence of alcoholism is extremely high. It is the most common drug problem in the United States, and we know that many physicians do not feel comfortable dealing with patients who have alcohol withdrawal,” Dr. Maldonado said, adding that this tool will simplify management.

For the Stanford study, patients with a negative PAWSS (score below 4) receive no treatment specifically for AWS. If they test positive (score of 4 or more), it is assumed that they will withdraw, and the AWS scale is administered to discriminate patients who are withdrawing from those at high risk of withdrawal. Patients with a positive PAWSS and a negative AWS scale or CIWA are directed to a prophylactic treatment arm. Those with a positive PAWSS and a positive AWS scale or CIWA are directed into a treatment arm, which involves more aggressive management.

The validation study was supported by the Chase Research Fund. Dr. Maldonado reported having no disclosures.

[email protected]

ATLANTA – A new scale for predicting complicated alcohol withdrawal syndrome in hospitalized medically ill patients had high sensitivity and specificity in a prospective validation study.

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) can help clinicians identify those at risk for complicated alcohol withdrawal syndrome (AWS), and either prevent or treat complicated AWS in a timely manner, Dr. José R. Maldonado of Stanford (Calif.) University said at the annual meeting of the American Psychiatric Association.

In 403 subjects hospitalized to general medicine and surgery units over a 12-month period, the PAWSS – along with the Clinical Institute Withdrawal Assessment–alcohol revised (CIWA-Ar) and clinical monitoring – was administered daily. Using a cutoff score of 4 on the 0-10 point PAWSS, the tool had sensitivity and positive predictive value of 93.1%, and specificity and negative predictive value of 99.5% for identifying complicated AWS, Dr. Maldonado said, noting that the tool also had excellent inter-rater reliability.

The findings are important because the prevalence of alcohol use disorders among hospitalized medically ill patients exceeds 40%, he said, noting that medically ill patients with AWS tend to have a significant number of complications, which makes them “not only very difficult to treat but also very high risk.”

Importantly, seizures – commonly known as “rum fits,” which occur in 5%-15% of cases – happen very early on in the course of AWS. This is a concern, because it has implications for prescribing, Dr. Maldonado said.

Another concern, and “probably the most dreadful of them all,” is delirium tremens (DTs), a severe symptom of alcohol withdrawal that occurs in about 10% of patients with AWS.

The overall mortality associated with DTs is 1% in non–medically ill patients, but in the medically ill, this figure increases to 20% because of the frequency of comorbidities, such as heart disease and diabetes in this population. Also, DTs tend to occur a few days into withdrawal, peaking on day 5, which could be problematic; a trauma patient who is intubated in the operating room, for example, still could go through withdrawal a few days later, as most medications being used in that patient are not going to prevent it, he explained.

Previously, no tool was available to predict complicated AWS to prevent seizures and DTs. Existing tools such as the CIWA and AWS scale assess AWS severity but do not predict who will withdraw, he noted, explaining that by the time the CIWA scale is positive, the patient already is in withdrawal.

One option is to treat everyone with benzodiazepines or other drugs that facilitate GABA (gamma-aminobutyric acid) transmission in patients at risk of AWS, but this unnecessarily puts 80% of patients at risk of numerous side effects, including excessive sedation, falls, respiratory depression, and medication-induced delirium.

A benzodiazepine-sparing protocol, which involved the use of alpha-2 agonists and anticonvulsants instead of benzodiazepines, was being studied at Stanford, comparing outcomes in patients treated with and without benzodiazepines.

“But before we started to use alpha-2 agonists and anticonvulsants ... we wanted to make sure that we were actually treating the population that really needs it. That was the main motivation for creating this tool,” he said. “The other thing is we wanted to make sure that we don’t scare people away from treating patients with potential alcohol withdrawal, because the consequences of withdrawal are dreadful, not only immediately but also into the future.”

Every time someone goes through withdrawal, it is more severe than before, and it lowers the threshold for DTs, he added.

An extensive literature review for anything associated with the various phases of alcohol withdrawal was performed to help develop the PAWSS, which includes 10 highly predictive questions for any patients who first indicate that they have had alcohol in the prior 30 days, or who is admitted with a positive blood alcohol level test.

A pilot study involving 70 patients yielded a sensitivity and specificity of 100% each, leading to the larger study of hospitalized patients, which was published last year in Alcohol and Alcoholism (2015 May 21. doi: 10.1093/alcalc/agv043).

A check of admission notes would have increased the ultimate sensitivity of the scale to 100%, as false answers provided on the scale were easily identified. Blood alcohol level testing also would help.

But PAWSS is meant to provide timely information, which is important in patients at risk, and another purpose for developing PAWSS was to provide an affordable tool that can be used anywhere, including rural community hospitals or clinics where other tests might not be available, Dr. Maldonado said.

Currently, he and his colleagues are evaluating whether all 10 items on the scale are needed to make a diagnosis, or whether a shorter version would be equally useful.

“The incidence of alcoholism is extremely high. It is the most common drug problem in the United States, and we know that many physicians do not feel comfortable dealing with patients who have alcohol withdrawal,” Dr. Maldonado said, adding that this tool will simplify management.

For the Stanford study, patients with a negative PAWSS (score below 4) receive no treatment specifically for AWS. If they test positive (score of 4 or more), it is assumed that they will withdraw, and the AWS scale is administered to discriminate patients who are withdrawing from those at high risk of withdrawal. Patients with a positive PAWSS and a negative AWS scale or CIWA are directed to a prophylactic treatment arm. Those with a positive PAWSS and a positive AWS scale or CIWA are directed into a treatment arm, which involves more aggressive management.

The validation study was supported by the Chase Research Fund. Dr. Maldonado reported having no disclosures.

[email protected]

ATLANTA – A new scale for predicting complicated alcohol withdrawal syndrome in hospitalized medically ill patients had high sensitivity and specificity in a prospective validation study.

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) can help clinicians identify those at risk for complicated alcohol withdrawal syndrome (AWS), and either prevent or treat complicated AWS in a timely manner, Dr. José R. Maldonado of Stanford (Calif.) University said at the annual meeting of the American Psychiatric Association.

In 403 subjects hospitalized to general medicine and surgery units over a 12-month period, the PAWSS – along with the Clinical Institute Withdrawal Assessment–alcohol revised (CIWA-Ar) and clinical monitoring – was administered daily. Using a cutoff score of 4 on the 0-10 point PAWSS, the tool had sensitivity and positive predictive value of 93.1%, and specificity and negative predictive value of 99.5% for identifying complicated AWS, Dr. Maldonado said, noting that the tool also had excellent inter-rater reliability.

The findings are important because the prevalence of alcohol use disorders among hospitalized medically ill patients exceeds 40%, he said, noting that medically ill patients with AWS tend to have a significant number of complications, which makes them “not only very difficult to treat but also very high risk.”

Importantly, seizures – commonly known as “rum fits,” which occur in 5%-15% of cases – happen very early on in the course of AWS. This is a concern, because it has implications for prescribing, Dr. Maldonado said.

Another concern, and “probably the most dreadful of them all,” is delirium tremens (DTs), a severe symptom of alcohol withdrawal that occurs in about 10% of patients with AWS.

The overall mortality associated with DTs is 1% in non–medically ill patients, but in the medically ill, this figure increases to 20% because of the frequency of comorbidities, such as heart disease and diabetes in this population. Also, DTs tend to occur a few days into withdrawal, peaking on day 5, which could be problematic; a trauma patient who is intubated in the operating room, for example, still could go through withdrawal a few days later, as most medications being used in that patient are not going to prevent it, he explained.

Previously, no tool was available to predict complicated AWS to prevent seizures and DTs. Existing tools such as the CIWA and AWS scale assess AWS severity but do not predict who will withdraw, he noted, explaining that by the time the CIWA scale is positive, the patient already is in withdrawal.

One option is to treat everyone with benzodiazepines or other drugs that facilitate GABA (gamma-aminobutyric acid) transmission in patients at risk of AWS, but this unnecessarily puts 80% of patients at risk of numerous side effects, including excessive sedation, falls, respiratory depression, and medication-induced delirium.

A benzodiazepine-sparing protocol, which involved the use of alpha-2 agonists and anticonvulsants instead of benzodiazepines, was being studied at Stanford, comparing outcomes in patients treated with and without benzodiazepines.

“But before we started to use alpha-2 agonists and anticonvulsants ... we wanted to make sure that we were actually treating the population that really needs it. That was the main motivation for creating this tool,” he said. “The other thing is we wanted to make sure that we don’t scare people away from treating patients with potential alcohol withdrawal, because the consequences of withdrawal are dreadful, not only immediately but also into the future.”

Every time someone goes through withdrawal, it is more severe than before, and it lowers the threshold for DTs, he added.

An extensive literature review for anything associated with the various phases of alcohol withdrawal was performed to help develop the PAWSS, which includes 10 highly predictive questions for any patients who first indicate that they have had alcohol in the prior 30 days, or who is admitted with a positive blood alcohol level test.

A pilot study involving 70 patients yielded a sensitivity and specificity of 100% each, leading to the larger study of hospitalized patients, which was published last year in Alcohol and Alcoholism (2015 May 21. doi: 10.1093/alcalc/agv043).

A check of admission notes would have increased the ultimate sensitivity of the scale to 100%, as false answers provided on the scale were easily identified. Blood alcohol level testing also would help.

But PAWSS is meant to provide timely information, which is important in patients at risk, and another purpose for developing PAWSS was to provide an affordable tool that can be used anywhere, including rural community hospitals or clinics where other tests might not be available, Dr. Maldonado said.

Currently, he and his colleagues are evaluating whether all 10 items on the scale are needed to make a diagnosis, or whether a shorter version would be equally useful.

“The incidence of alcoholism is extremely high. It is the most common drug problem in the United States, and we know that many physicians do not feel comfortable dealing with patients who have alcohol withdrawal,” Dr. Maldonado said, adding that this tool will simplify management.

For the Stanford study, patients with a negative PAWSS (score below 4) receive no treatment specifically for AWS. If they test positive (score of 4 or more), it is assumed that they will withdraw, and the AWS scale is administered to discriminate patients who are withdrawing from those at high risk of withdrawal. Patients with a positive PAWSS and a negative AWS scale or CIWA are directed to a prophylactic treatment arm. Those with a positive PAWSS and a positive AWS scale or CIWA are directed into a treatment arm, which involves more aggressive management.

The validation study was supported by the Chase Research Fund. Dr. Maldonado reported having no disclosures.

[email protected]

Granular Cell Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common human epithelial malignancy. There are several histologic variants, the rarest being granular cell BCC (GBCC).¹ Granular cell BCC is reported most commonly in men with a mean age of 63 years. Sixty-four percent of cases develop on the face, with the remainder arising on the chest or trunk. Granular cell BCC has distinct histologic features but has no specific epidemiologic or clinical features that differentiate it from more common forms of BCC. Treatment of GBCC is identical to BCC and demonstrates similar outcomes. The presence of granular cells can make GBCC difficult to differentiate from other benign and malignant lesions that display similar granular histologic changes.^1,2 Rarely, tumors that are histologically similar to human GBCC have been reported in animals.¹

Histologically, GBCC commonly demonstrates the architecture of a nodular BCC or may extend from an existing nodular BCC (quiz images A and B). Granular cell BCC is comprised of large islands of basaloid cells extending from the epidermis with rare mitotic activity. Certain variants showing no epidermal attachments have been described,^1,3 as in the current case. Classically, BCC and GBCC both demonstrate a peripheral palisade of blue basal cells; however, GBCC may lack this palisading feature in some cases. Therefore, GBCC may be comprised of granular cells only, which may be more easily confused with other tumors with granular cell differentiation. Even when GBCC retains the traditional peripheral palisade of blue basal cells, the central cells are filled with eosinophilic granules.^1,2

Electron microscopy of GBCC usually reveals bundles of cytoplasmic tonofilaments and desmosomes in both granular cells and the peripherally palisaded cells. Electron microscopy imaging also demonstrates 0.1- to 0.5-µm membrane-bound lysosomelike structures. In certain reports, these structures show focal positivity for lysozymes.^1,2 The etiology of the granules is unclear; however, they are thought to represent degenerative changes related to metabolic alteration and accumulation of lysosomelike structures. These lysosomelike structures have been highlighted with CD68 staining, which was negative in our case.^1,2 The lesional cells in GBCC stain positively for cytokeratins, p63, and Ber-EP4, and negatively for S-100 protein, epithelial membrane antigen, and carcinoembryonic antigen. The granules in GBCC generally are positive on periodic acid–Schiff staining.^1-4

The histologic differential diagnosis for GBCC includes granular cell tumor as well as other tumors that can present with granular cell changes such as ameloblastoma, leiomyoma, leiomyosarcoma, angiosarcoma, malignant peripheral nerve sheath tumor, and granular cell trichoblastoma. Granular cell ameloblastomas have histologic features and staining patterns that are identical to GBCC; however, ameloblastomas are distinguished by their location within the oral cavity. Granular cell tumors and malignant peripheral nerve sheath tumors stain positive for S-100 protein, and angiosarcomas stain positive for D2-40 and CD31. Leiomyomas and leiomyosarcomas can be differentiated by staining with smooth muscle actin or desmin.¹ Granular cell trichoblastomas can be differentiated by the follicular stem cell marker protein PHLDA1 positivity.⁵

Desmoplastic trichilemmoma is difficult to distinguish from BCC. These tumors are comprised of superficial lobules of basaloid cells with a perilobular hyaline mantel surrounding a central desmoplastic stroma (Figure 1). The basaloid cells in desmoplastic trichoepithelioma demonstrate clear cell change; however, granular features are not seen. The cells within the desmoplastic areas are arranged haphazardly in cords and nests and can mimic an invasive carcinoma; however, nuclear atypia and mitotic activity generally are absent in desmoplastic trichilemmoma.⁶

Granular cell tumors generally are poorly circumscribed dermal nodules comprised of large polygonal cells with an eosinophilic granular cytoplasm (Figure 2). The nuclei are generally small and round, and cytological atypia, necrosis, and mitotic activity are uncommon. The cells are positive for S-100 protein and neuron-specific enolase but negative for CD68. The granules are positive for periodic acid–Schiff stain and are diastase resistant. Rarely, these tumors can be malignant.⁷

Sebaceous adenoma is a well-circumscribed tumor comprised of lobules of characteristic mature sebocytes with bubbly or multivacuolated cytoplasm and crenated nuclei (Figure 3). There is an expansion and increased prominence of the peripherally located basaloid cells; however, in contrast to sebaceous epithelioma, less than 50% of the tumor usually is comprised of these basaloid cells.⁸

Xanthogranuloma demonstrates a dense collection of histiocytes in the dermis, commonly with Touton giant cell formation (Figure 4). The cells often have a foamy cytoplasm and cytoplasmic vacuoles are observed. The histiocytes are positive for factor XIIIa and CD68, and generally negative for S-100 protein and CD1a, which allows for differentiation from Langerhans cells.⁹

Granular Cell Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common human epithelial malignancy. There are several histologic variants, the rarest being granular cell BCC (GBCC).¹ Granular cell BCC is reported most commonly in men with a mean age of 63 years. Sixty-four percent of cases develop on the face, with the remainder arising on the chest or trunk. Granular cell BCC has distinct histologic features but has no specific epidemiologic or clinical features that differentiate it from more common forms of BCC. Treatment of GBCC is identical to BCC and demonstrates similar outcomes. The presence of granular cells can make GBCC difficult to differentiate from other benign and malignant lesions that display similar granular histologic changes.^1,2 Rarely, tumors that are histologically similar to human GBCC have been reported in animals.¹

Histologically, GBCC commonly demonstrates the architecture of a nodular BCC or may extend from an existing nodular BCC (quiz images A and B). Granular cell BCC is comprised of large islands of basaloid cells extending from the epidermis with rare mitotic activity. Certain variants showing no epidermal attachments have been described,^1,3 as in the current case. Classically, BCC and GBCC both demonstrate a peripheral palisade of blue basal cells; however, GBCC may lack this palisading feature in some cases. Therefore, GBCC may be comprised of granular cells only, which may be more easily confused with other tumors with granular cell differentiation. Even when GBCC retains the traditional peripheral palisade of blue basal cells, the central cells are filled with eosinophilic granules.^1,2

Electron microscopy of GBCC usually reveals bundles of cytoplasmic tonofilaments and desmosomes in both granular cells and the peripherally palisaded cells. Electron microscopy imaging also demonstrates 0.1- to 0.5-µm membrane-bound lysosomelike structures. In certain reports, these structures show focal positivity for lysozymes.^1,2 The etiology of the granules is unclear; however, they are thought to represent degenerative changes related to metabolic alteration and accumulation of lysosomelike structures. These lysosomelike structures have been highlighted with CD68 staining, which was negative in our case.^1,2 The lesional cells in GBCC stain positively for cytokeratins, p63, and Ber-EP4, and negatively for S-100 protein, epithelial membrane antigen, and carcinoembryonic antigen. The granules in GBCC generally are positive on periodic acid–Schiff staining.^1-4

The histologic differential diagnosis for GBCC includes granular cell tumor as well as other tumors that can present with granular cell changes such as ameloblastoma, leiomyoma, leiomyosarcoma, angiosarcoma, malignant peripheral nerve sheath tumor, and granular cell trichoblastoma. Granular cell ameloblastomas have histologic features and staining patterns that are identical to GBCC; however, ameloblastomas are distinguished by their location within the oral cavity. Granular cell tumors and malignant peripheral nerve sheath tumors stain positive for S-100 protein, and angiosarcomas stain positive for D2-40 and CD31. Leiomyomas and leiomyosarcomas can be differentiated by staining with smooth muscle actin or desmin.¹ Granular cell trichoblastomas can be differentiated by the follicular stem cell marker protein PHLDA1 positivity.⁵

Desmoplastic trichilemmoma is difficult to distinguish from BCC. These tumors are comprised of superficial lobules of basaloid cells with a perilobular hyaline mantel surrounding a central desmoplastic stroma (Figure 1). The basaloid cells in desmoplastic trichoepithelioma demonstrate clear cell change; however, granular features are not seen. The cells within the desmoplastic areas are arranged haphazardly in cords and nests and can mimic an invasive carcinoma; however, nuclear atypia and mitotic activity generally are absent in desmoplastic trichilemmoma.⁶

Granular cell tumors generally are poorly circumscribed dermal nodules comprised of large polygonal cells with an eosinophilic granular cytoplasm (Figure 2). The nuclei are generally small and round, and cytological atypia, necrosis, and mitotic activity are uncommon. The cells are positive for S-100 protein and neuron-specific enolase but negative for CD68. The granules are positive for periodic acid–Schiff stain and are diastase resistant. Rarely, these tumors can be malignant.⁷

Sebaceous adenoma is a well-circumscribed tumor comprised of lobules of characteristic mature sebocytes with bubbly or multivacuolated cytoplasm and crenated nuclei (Figure 3). There is an expansion and increased prominence of the peripherally located basaloid cells; however, in contrast to sebaceous epithelioma, less than 50% of the tumor usually is comprised of these basaloid cells.⁸

Xanthogranuloma demonstrates a dense collection of histiocytes in the dermis, commonly with Touton giant cell formation (Figure 4). The cells often have a foamy cytoplasm and cytoplasmic vacuoles are observed. The histiocytes are positive for factor XIIIa and CD68, and generally negative for S-100 protein and CD1a, which allows for differentiation from Langerhans cells.⁹

Granular Cell Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common human epithelial malignancy. There are several histologic variants, the rarest being granular cell BCC (GBCC).¹ Granular cell BCC is reported most commonly in men with a mean age of 63 years. Sixty-four percent of cases develop on the face, with the remainder arising on the chest or trunk. Granular cell BCC has distinct histologic features but has no specific epidemiologic or clinical features that differentiate it from more common forms of BCC. Treatment of GBCC is identical to BCC and demonstrates similar outcomes. The presence of granular cells can make GBCC difficult to differentiate from other benign and malignant lesions that display similar granular histologic changes.^1,2 Rarely, tumors that are histologically similar to human GBCC have been reported in animals.¹

Histologically, GBCC commonly demonstrates the architecture of a nodular BCC or may extend from an existing nodular BCC (quiz images A and B). Granular cell BCC is comprised of large islands of basaloid cells extending from the epidermis with rare mitotic activity. Certain variants showing no epidermal attachments have been described,^1,3 as in the current case. Classically, BCC and GBCC both demonstrate a peripheral palisade of blue basal cells; however, GBCC may lack this palisading feature in some cases. Therefore, GBCC may be comprised of granular cells only, which may be more easily confused with other tumors with granular cell differentiation. Even when GBCC retains the traditional peripheral palisade of blue basal cells, the central cells are filled with eosinophilic granules.^1,2

Electron microscopy of GBCC usually reveals bundles of cytoplasmic tonofilaments and desmosomes in both granular cells and the peripherally palisaded cells. Electron microscopy imaging also demonstrates 0.1- to 0.5-µm membrane-bound lysosomelike structures. In certain reports, these structures show focal positivity for lysozymes.^1,2 The etiology of the granules is unclear; however, they are thought to represent degenerative changes related to metabolic alteration and accumulation of lysosomelike structures. These lysosomelike structures have been highlighted with CD68 staining, which was negative in our case.^1,2 The lesional cells in GBCC stain positively for cytokeratins, p63, and Ber-EP4, and negatively for S-100 protein, epithelial membrane antigen, and carcinoembryonic antigen. The granules in GBCC generally are positive on periodic acid–Schiff staining.^1-4

The histologic differential diagnosis for GBCC includes granular cell tumor as well as other tumors that can present with granular cell changes such as ameloblastoma, leiomyoma, leiomyosarcoma, angiosarcoma, malignant peripheral nerve sheath tumor, and granular cell trichoblastoma. Granular cell ameloblastomas have histologic features and staining patterns that are identical to GBCC; however, ameloblastomas are distinguished by their location within the oral cavity. Granular cell tumors and malignant peripheral nerve sheath tumors stain positive for S-100 protein, and angiosarcomas stain positive for D2-40 and CD31. Leiomyomas and leiomyosarcomas can be differentiated by staining with smooth muscle actin or desmin.¹ Granular cell trichoblastomas can be differentiated by the follicular stem cell marker protein PHLDA1 positivity.⁵

Desmoplastic trichilemmoma is difficult to distinguish from BCC. These tumors are comprised of superficial lobules of basaloid cells with a perilobular hyaline mantel surrounding a central desmoplastic stroma (Figure 1). The basaloid cells in desmoplastic trichoepithelioma demonstrate clear cell change; however, granular features are not seen. The cells within the desmoplastic areas are arranged haphazardly in cords and nests and can mimic an invasive carcinoma; however, nuclear atypia and mitotic activity generally are absent in desmoplastic trichilemmoma.⁶

Granular cell tumors generally are poorly circumscribed dermal nodules comprised of large polygonal cells with an eosinophilic granular cytoplasm (Figure 2). The nuclei are generally small and round, and cytological atypia, necrosis, and mitotic activity are uncommon. The cells are positive for S-100 protein and neuron-specific enolase but negative for CD68. The granules are positive for periodic acid–Schiff stain and are diastase resistant. Rarely, these tumors can be malignant.⁷

Sebaceous adenoma is a well-circumscribed tumor comprised of lobules of characteristic mature sebocytes with bubbly or multivacuolated cytoplasm and crenated nuclei (Figure 3). There is an expansion and increased prominence of the peripherally located basaloid cells; however, in contrast to sebaceous epithelioma, less than 50% of the tumor usually is comprised of these basaloid cells.⁸

Xanthogranuloma demonstrates a dense collection of histiocytes in the dermis, commonly with Touton giant cell formation (Figure 4). The cells often have a foamy cytoplasm and cytoplasmic vacuoles are observed. The histiocytes are positive for factor XIIIa and CD68, and generally negative for S-100 protein and CD1a, which allows for differentiation from Langerhans cells.⁹

CHICAGO – Do anthracyclines still have a role in treating breast cancer? What are the implications for resistance of extending adjuvant aromatase inhibitors to 10 years or beyond? How best to treat women with metastatic hormone receptor–positive breast cancer, in light of findings on CDK 4/6 and mTOR inhibitors? Does sequence matter? In the case of HER2-positive disease, can a trastuzumab biosimilar be as effective as trastuzumab? And does a regimen with TDM-1 do more than reduce toxicity?

Dr. William A. Gradishar and Dr. Hope S. Rugo reflect on these questions and more in a video roundtable at the annual meeting of the American Society of Clinical Oncology.

Dr. William A. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago. He had no disclosures to report. Dr. Hope S. Rugo is professor of medicine at the University of California, San Francisco. She disclosed she is on the Speakers’ Bureau for Genomic Health and receives research funding (institutional) from Plexxikon, Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Lilly, GlaxoSmithKline, Genentech, Celsion, Nektar, and Merck.

[email protected]

On Twitter @NikolaidesLaura

CHICAGO – Do anthracyclines still have a role in treating breast cancer? What are the implications for resistance of extending adjuvant aromatase inhibitors to 10 years or beyond? How best to treat women with metastatic hormone receptor–positive breast cancer, in light of findings on CDK 4/6 and mTOR inhibitors? Does sequence matter? In the case of HER2-positive disease, can a trastuzumab biosimilar be as effective as trastuzumab? And does a regimen with TDM-1 do more than reduce toxicity?

Dr. William A. Gradishar and Dr. Hope S. Rugo reflect on these questions and more in a video roundtable at the annual meeting of the American Society of Clinical Oncology.

Dr. William A. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago. He had no disclosures to report. Dr. Hope S. Rugo is professor of medicine at the University of California, San Francisco. She disclosed she is on the Speakers’ Bureau for Genomic Health and receives research funding (institutional) from Plexxikon, Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Lilly, GlaxoSmithKline, Genentech, Celsion, Nektar, and Merck.

[email protected]

On Twitter @NikolaidesLaura

CHICAGO – Do anthracyclines still have a role in treating breast cancer? What are the implications for resistance of extending adjuvant aromatase inhibitors to 10 years or beyond? How best to treat women with metastatic hormone receptor–positive breast cancer, in light of findings on CDK 4/6 and mTOR inhibitors? Does sequence matter? In the case of HER2-positive disease, can a trastuzumab biosimilar be as effective as trastuzumab? And does a regimen with TDM-1 do more than reduce toxicity?

Dr. William A. Gradishar and Dr. Hope S. Rugo reflect on these questions and more in a video roundtable at the annual meeting of the American Society of Clinical Oncology.

Dr. William A. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago. He had no disclosures to report. Dr. Hope S. Rugo is professor of medicine at the University of California, San Francisco. She disclosed she is on the Speakers’ Bureau for Genomic Health and receives research funding (institutional) from Plexxikon, Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Lilly, GlaxoSmithKline, Genentech, Celsion, Nektar, and Merck.

[email protected]

On Twitter @NikolaidesLaura

CHICAGO – Agents that target the HER2, BRAF, Hedgehog, or EGFR pathways show promise in nonindicated tumor types that harbor these molecular alterations, according to early findings from the MyPathway study.

Of 129 patients enrolled in the multicenter, open-label, phase IIa study, 29 had a major response, defined as tumor shrinkage of at least 30%, to such treatment. One of those patients had a complete response, and 28 had a partial response. An additional 40 patients had stable disease on treatment. Fourteen of the 29 patients progressed after a median of 6 months’ follow-up, and 15 responses were ongoing at up to 11 months, Dr. John D. Hainsworth reported at the annual meeting of the American Society of Clinical Oncology.

©Gio_tto/Thinkstock.com

No new safety signals were observed, said Dr. Hainsworth of Sarah Cannon Research Institute in Nashville, Tenn.

Treatments evaluated in MyPathway included:

• Trastuzumab + pertuzumab, which targets the HER2 pathway and is currently indicated for breast cancer.

• Vemurafenib, which targets the BRAF pathway and is currently indicated for melanoma.

• Vismodegib, which targets the Hedgehog pathway and is currently indicated for basal cell carcinoma of the skin.

• Erlotinib, which targets the EGFR pathway and is indicated for non–small-cell lung cancer.

Responses have been seen with all four of the treatments, but the best responses were seen among patients with HER2 and BRAF abnormalities.

Among 61 cancers with HER2 amplification/overexpression, trastuzumab + pertuzumab provided a benefit for colorectal, bladder, biliary, non–small-cell lung, pancreas, and head/neck cancers.

Of 20 colorectal tumors, 7 (35%) showed complete or partial response, and 3 (15%) remained stable for at least 120 days (clinical benefit rate, 50%). Complete/partial responses and stable disease, respectively, were also seen in three and two of eight bladder tumors (clinical benefit rate, 63%), in three and three of six biliary tumors (clinical benefit rate, 100%), in two and zero of seven non–small-cell lung tumors (clinical benefit rate, 29%), one and zero of six pancreas tumors (clinical benefit rate, 17%), and one and zero of three head and neck tumors (34%). One of 11 other types of tumors showed disease stability at 120 days (clinical benefit rate, 9%). The overall clinical benefit rate in the study was 43%, Dr. Hainsworth said.

Among 33 cancers with the BRAF mutation, vemurafenib showed activity for non–small-cell lung, ovary, unknown primary, colorectal, pancreas, and head/neck tumors. Of 15 non–small-cell lung tumors, 3 (20%) showed complete or partial responses and 2 (13%) remained stable for at least 120 days (clinical benefit rate, 33%). Complete/partial responses and stable disease, respectively, were also seen in one and two of four ovary tumors (clinical benefit rate, 75%), and complete or partial responses were seen in one each of three unknown primary tumors, two colorectal tumors, two pancreas tumors, and one head/neck tumor (clinical benefit rates of 33%, 50%, 50%, and 100%, respectively). No benefit was seen with tumors at other sites (total clinical benefit rate, 36%), Dr. Hainsworth said.

“Of interest in this group [of patients with BRAF mutations], seven of the eight responses were in V600E mutations, and as you know, that’s the mutation that’s been specifically correlated with high response to BRAF inhibition in melanoma where this treatment is now approved,” he said, adding that the response rate in those patients was 38%.

Based on these early results, enrollment of patients with HER2 abnormalities and colorectal, bladder, or biliary cancer, and of patients with BRAF mutations and lung cancer, will be expanded, he said.

Subjects enrolled in MyPathway have advanced cancer showing abnormalities in any of the pathways of interest. The first 129 received a mean of three prior therapies, and in the 29 who responded, 12 different types of cancer responded to the targeted treatment.

“An increasing number of targeted agents for advanced cancer are in use now based on the presence of molecular abnormalities in the cancer. … We’ve known that the same mutations that are in those cancers are found in a wide variety of other cancers, although at a lower incidence, and it’s been difficult to test how effective these same treatments are for the other cancers due to the difficulty in identifying the patient population,” he said, explaining that an increase in comprehensive genomic profiling in recent years has allowed for identification of more and more of these mutations in other cancers.

“I think we’ve shown now that this trial design is feasible, where patients are selected on the basis of molecular abnormalities in their cancers rather than on their primary tumor type or primary site, and certainly offers opportunities for patients with these molecular abnormalities,” Dr. Hainsworth concluded.

Thus far, MyPathway has enrolled more than 200 patients, and is designed to accrue up to 500, with adjustment of treatment groups based on response rates. Emerging new regimens that target these pathways, such as the MEK inhibitor cobemetinib, will also be added, as will new agents targeting additional molecular abnormalities.

The study design, using this “tumor-agnostic approach,” mirrors that of the ASCO-led TAPUR trial, according to ASCO spokesperson Dr. Sumanta Kumar Pal.

The findings of these and other precision medicine trials may ultimately shift the longstanding cancer treatment paradigm, Dr. Pal said.

MyPathway received funding from Genentech. Dr. Hainsworth reported that his institution has received research funding from Astellas Pharma, AstraZeneca, Celgene, Genentech, Johnson & Johnson, Lilly, and Novartis.

[email protected]

CHICAGO – Agents that target the HER2, BRAF, Hedgehog, or EGFR pathways show promise in nonindicated tumor types that harbor these molecular alterations, according to early findings from the MyPathway study.

Of 129 patients enrolled in the multicenter, open-label, phase IIa study, 29 had a major response, defined as tumor shrinkage of at least 30%, to such treatment. One of those patients had a complete response, and 28 had a partial response. An additional 40 patients had stable disease on treatment. Fourteen of the 29 patients progressed after a median of 6 months’ follow-up, and 15 responses were ongoing at up to 11 months, Dr. John D. Hainsworth reported at the annual meeting of the American Society of Clinical Oncology.

©Gio_tto/Thinkstock.com

No new safety signals were observed, said Dr. Hainsworth of Sarah Cannon Research Institute in Nashville, Tenn.

Treatments evaluated in MyPathway included:

• Trastuzumab + pertuzumab, which targets the HER2 pathway and is currently indicated for breast cancer.

• Vemurafenib, which targets the BRAF pathway and is currently indicated for melanoma.

• Vismodegib, which targets the Hedgehog pathway and is currently indicated for basal cell carcinoma of the skin.

• Erlotinib, which targets the EGFR pathway and is indicated for non–small-cell lung cancer.

Responses have been seen with all four of the treatments, but the best responses were seen among patients with HER2 and BRAF abnormalities.

Among 61 cancers with HER2 amplification/overexpression, trastuzumab + pertuzumab provided a benefit for colorectal, bladder, biliary, non–small-cell lung, pancreas, and head/neck cancers.

Of 20 colorectal tumors, 7 (35%) showed complete or partial response, and 3 (15%) remained stable for at least 120 days (clinical benefit rate, 50%). Complete/partial responses and stable disease, respectively, were also seen in three and two of eight bladder tumors (clinical benefit rate, 63%), in three and three of six biliary tumors (clinical benefit rate, 100%), in two and zero of seven non–small-cell lung tumors (clinical benefit rate, 29%), one and zero of six pancreas tumors (clinical benefit rate, 17%), and one and zero of three head and neck tumors (34%). One of 11 other types of tumors showed disease stability at 120 days (clinical benefit rate, 9%). The overall clinical benefit rate in the study was 43%, Dr. Hainsworth said.

Among 33 cancers with the BRAF mutation, vemurafenib showed activity for non–small-cell lung, ovary, unknown primary, colorectal, pancreas, and head/neck tumors. Of 15 non–small-cell lung tumors, 3 (20%) showed complete or partial responses and 2 (13%) remained stable for at least 120 days (clinical benefit rate, 33%). Complete/partial responses and stable disease, respectively, were also seen in one and two of four ovary tumors (clinical benefit rate, 75%), and complete or partial responses were seen in one each of three unknown primary tumors, two colorectal tumors, two pancreas tumors, and one head/neck tumor (clinical benefit rates of 33%, 50%, 50%, and 100%, respectively). No benefit was seen with tumors at other sites (total clinical benefit rate, 36%), Dr. Hainsworth said.

“Of interest in this group [of patients with BRAF mutations], seven of the eight responses were in V600E mutations, and as you know, that’s the mutation that’s been specifically correlated with high response to BRAF inhibition in melanoma where this treatment is now approved,” he said, adding that the response rate in those patients was 38%.

Based on these early results, enrollment of patients with HER2 abnormalities and colorectal, bladder, or biliary cancer, and of patients with BRAF mutations and lung cancer, will be expanded, he said.

Subjects enrolled in MyPathway have advanced cancer showing abnormalities in any of the pathways of interest. The first 129 received a mean of three prior therapies, and in the 29 who responded, 12 different types of cancer responded to the targeted treatment.

“An increasing number of targeted agents for advanced cancer are in use now based on the presence of molecular abnormalities in the cancer. … We’ve known that the same mutations that are in those cancers are found in a wide variety of other cancers, although at a lower incidence, and it’s been difficult to test how effective these same treatments are for the other cancers due to the difficulty in identifying the patient population,” he said, explaining that an increase in comprehensive genomic profiling in recent years has allowed for identification of more and more of these mutations in other cancers.

“I think we’ve shown now that this trial design is feasible, where patients are selected on the basis of molecular abnormalities in their cancers rather than on their primary tumor type or primary site, and certainly offers opportunities for patients with these molecular abnormalities,” Dr. Hainsworth concluded.

Thus far, MyPathway has enrolled more than 200 patients, and is designed to accrue up to 500, with adjustment of treatment groups based on response rates. Emerging new regimens that target these pathways, such as the MEK inhibitor cobemetinib, will also be added, as will new agents targeting additional molecular abnormalities.

The study design, using this “tumor-agnostic approach,” mirrors that of the ASCO-led TAPUR trial, according to ASCO spokesperson Dr. Sumanta Kumar Pal.

The findings of these and other precision medicine trials may ultimately shift the longstanding cancer treatment paradigm, Dr. Pal said.

MyPathway received funding from Genentech. Dr. Hainsworth reported that his institution has received research funding from Astellas Pharma, AstraZeneca, Celgene, Genentech, Johnson & Johnson, Lilly, and Novartis.

[email protected]

CHICAGO – Agents that target the HER2, BRAF, Hedgehog, or EGFR pathways show promise in nonindicated tumor types that harbor these molecular alterations, according to early findings from the MyPathway study.

Of 129 patients enrolled in the multicenter, open-label, phase IIa study, 29 had a major response, defined as tumor shrinkage of at least 30%, to such treatment. One of those patients had a complete response, and 28 had a partial response. An additional 40 patients had stable disease on treatment. Fourteen of the 29 patients progressed after a median of 6 months’ follow-up, and 15 responses were ongoing at up to 11 months, Dr. John D. Hainsworth reported at the annual meeting of the American Society of Clinical Oncology.

©Gio_tto/Thinkstock.com

No new safety signals were observed, said Dr. Hainsworth of Sarah Cannon Research Institute in Nashville, Tenn.

Treatments evaluated in MyPathway included:

• Trastuzumab + pertuzumab, which targets the HER2 pathway and is currently indicated for breast cancer.

• Vemurafenib, which targets the BRAF pathway and is currently indicated for melanoma.

• Vismodegib, which targets the Hedgehog pathway and is currently indicated for basal cell carcinoma of the skin.

• Erlotinib, which targets the EGFR pathway and is indicated for non–small-cell lung cancer.

Responses have been seen with all four of the treatments, but the best responses were seen among patients with HER2 and BRAF abnormalities.

Among 61 cancers with HER2 amplification/overexpression, trastuzumab + pertuzumab provided a benefit for colorectal, bladder, biliary, non–small-cell lung, pancreas, and head/neck cancers.

Of 20 colorectal tumors, 7 (35%) showed complete or partial response, and 3 (15%) remained stable for at least 120 days (clinical benefit rate, 50%). Complete/partial responses and stable disease, respectively, were also seen in three and two of eight bladder tumors (clinical benefit rate, 63%), in three and three of six biliary tumors (clinical benefit rate, 100%), in two and zero of seven non–small-cell lung tumors (clinical benefit rate, 29%), one and zero of six pancreas tumors (clinical benefit rate, 17%), and one and zero of three head and neck tumors (34%). One of 11 other types of tumors showed disease stability at 120 days (clinical benefit rate, 9%). The overall clinical benefit rate in the study was 43%, Dr. Hainsworth said.

Among 33 cancers with the BRAF mutation, vemurafenib showed activity for non–small-cell lung, ovary, unknown primary, colorectal, pancreas, and head/neck tumors. Of 15 non–small-cell lung tumors, 3 (20%) showed complete or partial responses and 2 (13%) remained stable for at least 120 days (clinical benefit rate, 33%). Complete/partial responses and stable disease, respectively, were also seen in one and two of four ovary tumors (clinical benefit rate, 75%), and complete or partial responses were seen in one each of three unknown primary tumors, two colorectal tumors, two pancreas tumors, and one head/neck tumor (clinical benefit rates of 33%, 50%, 50%, and 100%, respectively). No benefit was seen with tumors at other sites (total clinical benefit rate, 36%), Dr. Hainsworth said.

“Of interest in this group [of patients with BRAF mutations], seven of the eight responses were in V600E mutations, and as you know, that’s the mutation that’s been specifically correlated with high response to BRAF inhibition in melanoma where this treatment is now approved,” he said, adding that the response rate in those patients was 38%.

Based on these early results, enrollment of patients with HER2 abnormalities and colorectal, bladder, or biliary cancer, and of patients with BRAF mutations and lung cancer, will be expanded, he said.

Subjects enrolled in MyPathway have advanced cancer showing abnormalities in any of the pathways of interest. The first 129 received a mean of three prior therapies, and in the 29 who responded, 12 different types of cancer responded to the targeted treatment.

“An increasing number of targeted agents for advanced cancer are in use now based on the presence of molecular abnormalities in the cancer. … We’ve known that the same mutations that are in those cancers are found in a wide variety of other cancers, although at a lower incidence, and it’s been difficult to test how effective these same treatments are for the other cancers due to the difficulty in identifying the patient population,” he said, explaining that an increase in comprehensive genomic profiling in recent years has allowed for identification of more and more of these mutations in other cancers.

“I think we’ve shown now that this trial design is feasible, where patients are selected on the basis of molecular abnormalities in their cancers rather than on their primary tumor type or primary site, and certainly offers opportunities for patients with these molecular abnormalities,” Dr. Hainsworth concluded.

Thus far, MyPathway has enrolled more than 200 patients, and is designed to accrue up to 500, with adjustment of treatment groups based on response rates. Emerging new regimens that target these pathways, such as the MEK inhibitor cobemetinib, will also be added, as will new agents targeting additional molecular abnormalities.

The study design, using this “tumor-agnostic approach,” mirrors that of the ASCO-led TAPUR trial, according to ASCO spokesperson Dr. Sumanta Kumar Pal.

The findings of these and other precision medicine trials may ultimately shift the longstanding cancer treatment paradigm, Dr. Pal said.

MyPathway received funding from Genentech. Dr. Hainsworth reported that his institution has received research funding from Astellas Pharma, AstraZeneca, Celgene, Genentech, Johnson & Johnson, Lilly, and Novartis.

[email protected]

Shoulder arthroplasty (SA), including total SA (TSA) and reverse TSA, is an effective surgical treatment for fracture and primary or secondary degenerative disease of the shoulder.¹ Over the past few decades, use of SA has increased dramatically, from about 5000 cases in 1990 to 7000 in 2000 and more than 26,000 in 2008.^1,2

Complications associated with SA generally are classified as perioperative (occurring during the operative index) or long-term (postdischarge).³ Long-term complications include implant loosening, instability, revision, infection, rotator cuff tear, neural injury, and deltoid detachment.^1,4,5 Perioperative complications, which are less commonly reported, include intraoperative fracture, infection, neural injury, venous thromboembolic events (VTEs, including pulmonary embolism [PE] and deep vein thrombosis [DVT]), transfusion, and death.^3,6-10

SA is an attractive treatment option for patients with rheumatoid arthritis (RA), as the effects of pain on these patients are greater in the shoulder joint than in any other joint.¹¹ Patients with RA pose unique orthopedic surgical challenges, including any combination of decreased bone mineralization, poor capsular tissue integrity, and osteonecrosis.^3,12 In addition, RA patients may be taking immunosuppressive medications that have severe side effects, and they may require multiple surgeries.^12,13 These factors predispose patients with RA to complications that include infection and wound dehiscence.^3,5,12-14

The complex nature of RA has prompted investigators to examine outcome measures in this patient group. Hambright and colleagues³ used the Nationwide Inpatient Sample (NIS) to examine perioperative outcomes in RA patients who underwent TSA between 1988 and 2005.³ They found that TSA patients with RA had shorter and less costly hospital stays and were more likely to have a routine discharge.³ Using the same patient population drawn from the period 2006–2011, we conducted a study to determine if this unexpected trend persists as the number of TSAs and quality of postoperative care continue to increase. Given the potential for anemia of chronic disease and the systemic inflammatory nature of RA, we hypothesized that the perioperative complication profile of RA patients would be worse than that of non-RA patients.

Materials and Methods

NIS data were acquired for the period 2006–2011. The NIS is the largest publicly available all-payer inpatient database, with a random 20% sample of about 1000 US hospitals accounting for 7 to 8 million inpatient stays. The database supplies weights used to estimate national totals, at about 35 million inpatient visits per year. NIS inpatient data are limited to the operative index. Postdischarge information is not available. The NIS is managed by the Healthcare Cost and Utilization Project, which is sponsored by the Agency for Healthcare Research and Quality. The quality of NIS data is assessed and validated by an independent contractor. NIS data have been widely used to examine perioperative outcomes.^15-17

NIS data cover patient and hospital demographics, hospital length of stay (LOS), discharge status, payer information, charges, and perioperative outcomes and procedure/diagnosis codes (ICD-9; International Classification of Diseases, Ninth Revision¹⁸).

As our Institutional Review Board (IRB) reviewed the database and determined the project was not human subject research, IRB involvement was not required. This study paralleled successful efforts with similar RA and non-RA patients who had shoulder and elbow surgery.^3,19 SA patients were identified by ICD-9 procedure code 81.80, but this code does not specify whether the prosthesis was unconstrained, semiconstrained, or constrained. ICD-9 coding also does not specify whether the TSA was traditional or reverse. Patients with RA were identified by ICD-9 diagnosis codes 714.0, 714.1, and 714.2. Patients without one of these codes were placed in the non-RA cohort. Patients with codes associated with pathologic fractures secondary to metastatic cancer or bone malignant neoplasm as a secondary or primary diagnosis and patients who had revision surgery indicated by code 81.83 were excluded, as they have a disproportionately higher comorbidity burden.

After each cohort was defined, demographic data (age, sex, race, income quartile based on ZIP postal code) were compared, as were data on primary payer, hospital demographics, LOS (≤5 days, defined as perioperative index), discharge type, inflation-adjusted charges in 2014 dollars based on the Consumer Price Indexes (http://www.bls.gov/cpi/), and mortality. Perioperative complications—respiratory, gastrointestinal, genitourinary, accidental puncture/laceration, central nervous system, wound dehiscence, device-related (including embolism, fibrosis, hemorrhage, pain, stenosis, or thrombus caused by any device, implant, or graft), cardiac, hematoma/seroma, acute respiratory distress syndrome, postoperative shock, VTE, postoperative infection complications, and intraoperative transfusions—were considered using ICD-9 codes (996.X-999.X and 99.X, respectively).²⁰ Although commonly used to determine perioperative comorbidity burden using ICD-9 coding, the modified Charlson index was not considered because RA is a component of the index and would therefore bias the variable.^3,21

Statistical analyses, including χ² tests and 2-sample t tests, were performed for categorical and continuous variables, respectively. P < .05 was considered significant. Fisher exact test was used for cohorts with fewer than 5 occurrences. Multivariate logistic regression models were then calculated to determine the effect of RA on different outcomes and complications, with age, race, sex, hospital region, hospital type, number of hospital beds, primary payer, and hospital ownership as covariates. Statistical analyses were performed using the R statistical programming language.22

Results

Of the 34,970 patients who underwent SA between 2006 and 2011, 1674 (4.8%) had a diagnosis of RA and 33,296 (95.2%) did not. On average, patients with RA tended to be younger than patients without RA (66.4 vs 69.1 years; P < .001), and a larger percentage of RA patients were female (75.5% vs 54.4%; P < .001). Compared with non-RA patients, RA patients comprised a different ethnic group and had a different expected primary payer (P < .001). SA patients with and without RA did not differ in income quartile based on ZIP code, total number of hospital beds, hospital region, or hospital teaching status (P = .34, .78, .59, and .82, respectively) (Table 1).

LOS was significantly (P < .001) statistically longer for RA patients (2.196 days) than for non-RA patients (2.085 days). RA patients were significantly less likely to be discharged home (63.0% vs 67.6%; P < .001). (Routine discharge was defined as discharge home, whereas nonroutine discharge was defined as discharge to a short-term hospital, skilled nursing facility, intermediate care, another type of facility, home health care, against medical advice, or death.) In addition, inflation-adjusted charges associated with SA were significantly higher (P = .018) for RA patients ($54,284) than for non-RA patients ($52,663) (Table 1).

Regarding the rates of complications that occurred during the perioperative index, there were no significant differences between RA and non-RA cohorts. These complications included respiratory, gastrointestinal, genitourinary, accidental puncture/laceration, central nervous system, wound dehiscence, device-related, cardiac, hematoma/seroma, acute respiratory distress syndrome, postoperative shock, VTE, and postoperative infection (Table 2). In addition, there was no significant difference in mortality between the groups (P = .48).

In TSA, blood transfusions were more likely (P < .001) to be given to RA patients (9.00%) than to non-RA patients (6.16%). Multivariate regression analyses were performed with age, race, sex, hospital region, hospital type, number of hospital beds, primary payer, and hospital ownership as covariates. These analyses revealed that transfusion (P < .001), discharge type (P = .002), total inflation-adjusted charges (P < .001), and LOS (P = .047) remained significant (Table 3).

Discussion

Large national databases like NIS allow study of uncommon medical occurrences and help delineate risks and trends that otherwise might be indeterminable. Although it has been suggested that patients with RA may have poorer long-term outcomes after SA, the perioperative risk profile indicates that TSA is well tolerated in RA patients during the operative index.^3,23-25

The data on this study’s 34,970 patients, drawn from the period 2006–2011, demonstrated no significant differences in safety profile with respect to the 14 perioperative complications and outcomes examined, except blood transfusion rate. Rates of postoperative infection (RA, 0.24%; non-RA, 0.14%; P = .303), VTE (RA, 0.30%; non-RA, 0.25%; P = .905), and transfusion (RA, 9.00%; non-RA, 6.16%; P < .001) are of particular interest because of the severity of these situations.

Postoperative infection is a potentially serious complication and often occurs secondary to diabetes, RA, lupus erythematosus, prior surgery, or a nosocomial or remote source.¹ The often costly treatment options include antibiotic suppression, irrigation and debridement with implant retention, 1-stage exchange with antibiotic-impregnated cement fixation, staged reimplantation, resection arthroplasty, arthrodesis, and amputation.¹ The overall 0.14% infection rate determined in this study is lower than the 0.7% reported for SA patients in the literature.¹ Given the nature of the NIS database, this rate underestimates the true postoperative infection rate, as any infection that occurred after the perioperative period is not captured.²⁶ The present study’s perioperative infection rates (RA, 0.24%; non-RA, 0.14%) for the period 2006–2011 are comparable to the rates (RA, 0.17%; non-RA, 0.24%) reported by Hambright and colleagues3 for the same patient population over the preceding, 18-year period (1988–2005) and similarly do not significantly differ between groups. Although infection is uncommon in the immediate perioperative period, the ICD-9 codes used refer specifically to infection resulting from surgery and do not represent concomitant infection.

VTEs, which include PEs and DVTs, are rare but potentially life-threatening surgical complications.^27,28 Mechanical prophylaxis and chemical prophylaxis have been recommended for major orthopedic surgery, particularly lower extremity surgery, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA).^28,29 In the present study, VTE rates were low, 0.30% (RA) and 0.25% (non-RA), and not significantly different in bivariate or multivariate analyses. These rates are comparable to those found in other national-database SA studies.²⁸ VTEs that occur outside the index hospital admission are not captured in this database. Therefore, the rates in the present study may be lower than the true incidence after SA. Mortality secondary to VTE usually occurs within 24 hours but may occur up to 90 days after surgery. DVT rates, on the other hand, are difficult to evaluate because of differences in screening practices.^27,28,30,31

That RA patients were more likely than non-RA patients to receive perioperative blood transfusions supports prior findings that SA patients with RA were more likely than SA patients with osteoarthritis (OA) to receive perioperative blood transfusions.⁸ RA patients have been shown to have high rates of anemia of chronic disease, ranging from 22% to 77%.³² During joint replacement, these patients often require transfusions.^32,33 However, these findings differ from prior findings of no differences between RA and non-RA patients in the same patient population during the period 1988–2005.³ This difference may be a product of the constantly changing transfusion guidelines and increased use; transfusion rates increased 140% between 1997 and 2007, making transfusions the fastest growing common procedure in the United States during that time.³⁴ There was no difference between RA and non-RA patients in household income (as determined by ZIP code analysis), number of hospital beds, hospital region, or hospital teaching status. Compared with non-RA patients, RA patients were more likely to be younger, female, and of a difference race and to have a different expected primary payer (P < .001).These findings are consistent with previous findings in the literature.³ In the present SA study, however, RA patients were more likely than non-RA patients to have longer LOS, higher inflation-adjusted hospital charges, and nonroutine discharge. These findings deviate from those of the study covering the preceding 18 years (1988–2005).³ Despite the findings of a changing environment of care for RA patients, by Hambright and colleagues³ and Weiss and colleagues,³⁵ the trend appears to have shifted. Both groups had shorter average LOS than either group from the preceding 18 years.³ Although statistically significant in bivariate analysis, the difference in LOS between the 2 groups differed by an average of 0.11 day (2 hours 24 minutes) and was not clinically relevant.

In addition, the higher charges for patients with RA represent a deviation from the preceding 18 years.³ Other studies have also shown that RA is associated with increased cost in TSA.³⁶ Patients with RA often have rotator cuff pathology, indicating reverse SA may be used more frequently.^37,38 The increased implant cost associated with reverse SA may account for the increased costs in RA patients.³⁹ As mentioned, TSA type is not captured in the NIS database. In addition, that RA patients were less likely than non-RA patients to have routine discharge may indicate RA cases are more complex because of their complications.^1,5,14,40 A recent study of complications in RA patients (1163 who underwent THA, 2692 who underwent TKA) found that THA patients with RA were significantly more likely than THA patients with OA to dislocate, and TKA patients with RA were significantly more likely than TKA patients with OA to develop an infection after surgery.⁴¹ Postoperative dislocation has been shown to increase hospital costs in other orthopedic procedures.⁴² Also, during TSA, patients with RA are more likely than patients with OA to receive intraoperative blood transfusions.⁸ These complications—combined with the fact that RA is a chronic, progressive, systemic inflammatory disease that can affect soft tissue and blood vessel wall healing and is associated with medications having potential side effects—could contribute to the apparent increased hospital charges and LOS.^3,12,13,43 Factors that include surgeon preference, impact of primary payer, and hospital practice may also affect final charges. Total charges in the NIS database include administrative fees, hospital costs, device-related costs, operating room costs, and ancillary staff costs. Total charges do not include professional fees and differ from the total cost that represents the amount reimbursed by the payer. Charges tend to correlate with but overestimate the total costs.⁴⁴

This study had several important limitations. As mentioned, only events that occur during the operative admission are captured in the NIS database, and thus postoperative complications or serious adverse events that lead to readmission cannot be identified. In addition, outpatient TSAs are not captured in the NIS database, and thus inclusion of only inpatient procedures yields higher average LOS and total charges.⁴⁵ Given the limited granularity of ICD-9 coding, this study could not determine RA severity, estimated blood loss, length of surgery, complication severity, type of TSA procedure/prosthesis, or cause of death. Although commonly used to determine comorbidity burden, the modified Charlson index could not be used, and therefore could not be entered as a covariate in multivariate analysis. Furthermore, the NIS database does not include imaging or patient-reported outcomes information, such as improvements in pain or function, which are of crucial importance in considering surgery.

Conclusion

Our findings corroborated findings that the demographics and the perioperative safety profile for TSA were similar for patients with and without RA. The risk for complications or death in the perioperative period was low. Compared with non-RA patients, RA patients had significantly higher charges and longer LOS and were less likely to be discharged home after surgery. The 0.11-day difference in LOS, though statistically significant, was not clinically relevant. These findings differ from those for the preceding, 18-year period (1988–2005). Future research should focus on the causes of these changes.

Shoulder arthroplasty (SA), including total SA (TSA) and reverse TSA, is an effective surgical treatment for fracture and primary or secondary degenerative disease of the shoulder.¹ Over the past few decades, use of SA has increased dramatically, from about 5000 cases in 1990 to 7000 in 2000 and more than 26,000 in 2008.^1,2

Complications associated with SA generally are classified as perioperative (occurring during the operative index) or long-term (postdischarge).³ Long-term complications include implant loosening, instability, revision, infection, rotator cuff tear, neural injury, and deltoid detachment.^1,4,5 Perioperative complications, which are less commonly reported, include intraoperative fracture, infection, neural injury, venous thromboembolic events (VTEs, including pulmonary embolism [PE] and deep vein thrombosis [DVT]), transfusion, and death.^3,6-10

SA is an attractive treatment option for patients with rheumatoid arthritis (RA), as the effects of pain on these patients are greater in the shoulder joint than in any other joint.¹¹ Patients with RA pose unique orthopedic surgical challenges, including any combination of decreased bone mineralization, poor capsular tissue integrity, and osteonecrosis.^3,12 In addition, RA patients may be taking immunosuppressive medications that have severe side effects, and they may require multiple surgeries.^12,13 These factors predispose patients with RA to complications that include infection and wound dehiscence.^3,5,12-14

The complex nature of RA has prompted investigators to examine outcome measures in this patient group. Hambright and colleagues³ used the Nationwide Inpatient Sample (NIS) to examine perioperative outcomes in RA patients who underwent TSA between 1988 and 2005.³ They found that TSA patients with RA had shorter and less costly hospital stays and were more likely to have a routine discharge.³ Using the same patient population drawn from the period 2006–2011, we conducted a study to determine if this unexpected trend persists as the number of TSAs and quality of postoperative care continue to increase. Given the potential for anemia of chronic disease and the systemic inflammatory nature of RA, we hypothesized that the perioperative complication profile of RA patients would be worse than that of non-RA patients.

Materials and Methods

NIS data were acquired for the period 2006–2011. The NIS is the largest publicly available all-payer inpatient database, with a random 20% sample of about 1000 US hospitals accounting for 7 to 8 million inpatient stays. The database supplies weights used to estimate national totals, at about 35 million inpatient visits per year. NIS inpatient data are limited to the operative index. Postdischarge information is not available. The NIS is managed by the Healthcare Cost and Utilization Project, which is sponsored by the Agency for Healthcare Research and Quality. The quality of NIS data is assessed and validated by an independent contractor. NIS data have been widely used to examine perioperative outcomes.^15-17

NIS data cover patient and hospital demographics, hospital length of stay (LOS), discharge status, payer information, charges, and perioperative outcomes and procedure/diagnosis codes (ICD-9; International Classification of Diseases, Ninth Revision¹⁸).

As our Institutional Review Board (IRB) reviewed the database and determined the project was not human subject research, IRB involvement was not required. This study paralleled successful efforts with similar RA and non-RA patients who had shoulder and elbow surgery.^3,19 SA patients were identified by ICD-9 procedure code 81.80, but this code does not specify whether the prosthesis was unconstrained, semiconstrained, or constrained. ICD-9 coding also does not specify whether the TSA was traditional or reverse. Patients with RA were identified by ICD-9 diagnosis codes 714.0, 714.1, and 714.2. Patients without one of these codes were placed in the non-RA cohort. Patients with codes associated with pathologic fractures secondary to metastatic cancer or bone malignant neoplasm as a secondary or primary diagnosis and patients who had revision surgery indicated by code 81.83 were excluded, as they have a disproportionately higher comorbidity burden.

After each cohort was defined, demographic data (age, sex, race, income quartile based on ZIP postal code) were compared, as were data on primary payer, hospital demographics, LOS (≤5 days, defined as perioperative index), discharge type, inflation-adjusted charges in 2014 dollars based on the Consumer Price Indexes (http://www.bls.gov/cpi/), and mortality. Perioperative complications—respiratory, gastrointestinal, genitourinary, accidental puncture/laceration, central nervous system, wound dehiscence, device-related (including embolism, fibrosis, hemorrhage, pain, stenosis, or thrombus caused by any device, implant, or graft), cardiac, hematoma/seroma, acute respiratory distress syndrome, postoperative shock, VTE, postoperative infection complications, and intraoperative transfusions—were considered using ICD-9 codes (996.X-999.X and 99.X, respectively).²⁰ Although commonly used to determine perioperative comorbidity burden using ICD-9 coding, the modified Charlson index was not considered because RA is a component of the index and would therefore bias the variable.^3,21

Statistical analyses, including χ² tests and 2-sample t tests, were performed for categorical and continuous variables, respectively. P < .05 was considered significant. Fisher exact test was used for cohorts with fewer than 5 occurrences. Multivariate logistic regression models were then calculated to determine the effect of RA on different outcomes and complications, with age, race, sex, hospital region, hospital type, number of hospital beds, primary payer, and hospital ownership as covariates. Statistical analyses were performed using the R statistical programming language.22

Results

Of the 34,970 patients who underwent SA between 2006 and 2011, 1674 (4.8%) had a diagnosis of RA and 33,296 (95.2%) did not. On average, patients with RA tended to be younger than patients without RA (66.4 vs 69.1 years; P < .001), and a larger percentage of RA patients were female (75.5% vs 54.4%; P < .001). Compared with non-RA patients, RA patients comprised a different ethnic group and had a different expected primary payer (P < .001). SA patients with and without RA did not differ in income quartile based on ZIP code, total number of hospital beds, hospital region, or hospital teaching status (P = .34, .78, .59, and .82, respectively) (Table 1).

LOS was significantly (P < .001) statistically longer for RA patients (2.196 days) than for non-RA patients (2.085 days). RA patients were significantly less likely to be discharged home (63.0% vs 67.6%; P < .001). (Routine discharge was defined as discharge home, whereas nonroutine discharge was defined as discharge to a short-term hospital, skilled nursing facility, intermediate care, another type of facility, home health care, against medical advice, or death.) In addition, inflation-adjusted charges associated with SA were significantly higher (P = .018) for RA patients ($54,284) than for non-RA patients ($52,663) (Table 1).

Regarding the rates of complications that occurred during the perioperative index, there were no significant differences between RA and non-RA cohorts. These complications included respiratory, gastrointestinal, genitourinary, accidental puncture/laceration, central nervous system, wound dehiscence, device-related, cardiac, hematoma/seroma, acute respiratory distress syndrome, postoperative shock, VTE, and postoperative infection (Table 2). In addition, there was no significant difference in mortality between the groups (P = .48).

In TSA, blood transfusions were more likely (P < .001) to be given to RA patients (9.00%) than to non-RA patients (6.16%). Multivariate regression analyses were performed with age, race, sex, hospital region, hospital type, number of hospital beds, primary payer, and hospital ownership as covariates. These analyses revealed that transfusion (P < .001), discharge type (P = .002), total inflation-adjusted charges (P < .001), and LOS (P = .047) remained significant (Table 3).

Discussion

Large national databases like NIS allow study of uncommon medical occurrences and help delineate risks and trends that otherwise might be indeterminable. Although it has been suggested that patients with RA may have poorer long-term outcomes after SA, the perioperative risk profile indicates that TSA is well tolerated in RA patients during the operative index.^3,23-25

The data on this study’s 34,970 patients, drawn from the period 2006–2011, demonstrated no significant differences in safety profile with respect to the 14 perioperative complications and outcomes examined, except blood transfusion rate. Rates of postoperative infection (RA, 0.24%; non-RA, 0.14%; P = .303), VTE (RA, 0.30%; non-RA, 0.25%; P = .905), and transfusion (RA, 9.00%; non-RA, 6.16%; P < .001) are of particular interest because of the severity of these situations.

Postoperative infection is a potentially serious complication and often occurs secondary to diabetes, RA, lupus erythematosus, prior surgery, or a nosocomial or remote source.¹ The often costly treatment options include antibiotic suppression, irrigation and debridement with implant retention, 1-stage exchange with antibiotic-impregnated cement fixation, staged reimplantation, resection arthroplasty, arthrodesis, and amputation.¹ The overall 0.14% infection rate determined in this study is lower than the 0.7% reported for SA patients in the literature.¹ Given the nature of the NIS database, this rate underestimates the true postoperative infection rate, as any infection that occurred after the perioperative period is not captured.²⁶ The present study’s perioperative infection rates (RA, 0.24%; non-RA, 0.14%) for the period 2006–2011 are comparable to the rates (RA, 0.17%; non-RA, 0.24%) reported by Hambright and colleagues3 for the same patient population over the preceding, 18-year period (1988–2005) and similarly do not significantly differ between groups. Although infection is uncommon in the immediate perioperative period, the ICD-9 codes used refer specifically to infection resulting from surgery and do not represent concomitant infection.

VTEs, which include PEs and DVTs, are rare but potentially life-threatening surgical complications.^27,28 Mechanical prophylaxis and chemical prophylaxis have been recommended for major orthopedic surgery, particularly lower extremity surgery, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA).^28,29 In the present study, VTE rates were low, 0.30% (RA) and 0.25% (non-RA), and not significantly different in bivariate or multivariate analyses. These rates are comparable to those found in other national-database SA studies.²⁸ VTEs that occur outside the index hospital admission are not captured in this database. Therefore, the rates in the present study may be lower than the true incidence after SA. Mortality secondary to VTE usually occurs within 24 hours but may occur up to 90 days after surgery. DVT rates, on the other hand, are difficult to evaluate because of differences in screening practices.^27,28,30,31

That RA patients were more likely than non-RA patients to receive perioperative blood transfusions supports prior findings that SA patients with RA were more likely than SA patients with osteoarthritis (OA) to receive perioperative blood transfusions.⁸ RA patients have been shown to have high rates of anemia of chronic disease, ranging from 22% to 77%.³² During joint replacement, these patients often require transfusions.^32,33 However, these findings differ from prior findings of no differences between RA and non-RA patients in the same patient population during the period 1988–2005.³ This difference may be a product of the constantly changing transfusion guidelines and increased use; transfusion rates increased 140% between 1997 and 2007, making transfusions the fastest growing common procedure in the United States during that time.³⁴ There was no difference between RA and non-RA patients in household income (as determined by ZIP code analysis), number of hospital beds, hospital region, or hospital teaching status. Compared with non-RA patients, RA patients were more likely to be younger, female, and of a difference race and to have a different expected primary payer (P < .001).These findings are consistent with previous findings in the literature.³ In the present SA study, however, RA patients were more likely than non-RA patients to have longer LOS, higher inflation-adjusted hospital charges, and nonroutine discharge. These findings deviate from those of the study covering the preceding 18 years (1988–2005).³ Despite the findings of a changing environment of care for RA patients, by Hambright and colleagues³ and Weiss and colleagues,³⁵ the trend appears to have shifted. Both groups had shorter average LOS than either group from the preceding 18 years.³ Although statistically significant in bivariate analysis, the difference in LOS between the 2 groups differed by an average of 0.11 day (2 hours 24 minutes) and was not clinically relevant.

In addition, the higher charges for patients with RA represent a deviation from the preceding 18 years.³ Other studies have also shown that RA is associated with increased cost in TSA.³⁶ Patients with RA often have rotator cuff pathology, indicating reverse SA may be used more frequently.^37,38 The increased implant cost associated with reverse SA may account for the increased costs in RA patients.³⁹ As mentioned, TSA type is not captured in the NIS database. In addition, that RA patients were less likely than non-RA patients to have routine discharge may indicate RA cases are more complex because of their complications.^1,5,14,40 A recent study of complications in RA patients (1163 who underwent THA, 2692 who underwent TKA) found that THA patients with RA were significantly more likely than THA patients with OA to dislocate, and TKA patients with RA were significantly more likely than TKA patients with OA to develop an infection after surgery.⁴¹ Postoperative dislocation has been shown to increase hospital costs in other orthopedic procedures.⁴² Also, during TSA, patients with RA are more likely than patients with OA to receive intraoperative blood transfusions.⁸ These complications—combined with the fact that RA is a chronic, progressive, systemic inflammatory disease that can affect soft tissue and blood vessel wall healing and is associated with medications having potential side effects—could contribute to the apparent increased hospital charges and LOS.^3,12,13,43 Factors that include surgeon preference, impact of primary payer, and hospital practice may also affect final charges. Total charges in the NIS database include administrative fees, hospital costs, device-related costs, operating room costs, and ancillary staff costs. Total charges do not include professional fees and differ from the total cost that represents the amount reimbursed by the payer. Charges tend to correlate with but overestimate the total costs.⁴⁴

This study had several important limitations. As mentioned, only events that occur during the operative admission are captured in the NIS database, and thus postoperative complications or serious adverse events that lead to readmission cannot be identified. In addition, outpatient TSAs are not captured in the NIS database, and thus inclusion of only inpatient procedures yields higher average LOS and total charges.⁴⁵ Given the limited granularity of ICD-9 coding, this study could not determine RA severity, estimated blood loss, length of surgery, complication severity, type of TSA procedure/prosthesis, or cause of death. Although commonly used to determine comorbidity burden, the modified Charlson index could not be used, and therefore could not be entered as a covariate in multivariate analysis. Furthermore, the NIS database does not include imaging or patient-reported outcomes information, such as improvements in pain or function, which are of crucial importance in considering surgery.

Conclusion

Our findings corroborated findings that the demographics and the perioperative safety profile for TSA were similar for patients with and without RA. The risk for complications or death in the perioperative period was low. Compared with non-RA patients, RA patients had significantly higher charges and longer LOS and were less likely to be discharged home after surgery. The 0.11-day difference in LOS, though statistically significant, was not clinically relevant. These findings differ from those for the preceding, 18-year period (1988–2005). Future research should focus on the causes of these changes.

Shoulder arthroplasty (SA), including total SA (TSA) and reverse TSA, is an effective surgical treatment for fracture and primary or secondary degenerative disease of the shoulder.¹ Over the past few decades, use of SA has increased dramatically, from about 5000 cases in 1990 to 7000 in 2000 and more than 26,000 in 2008.^1,2

Complications associated with SA generally are classified as perioperative (occurring during the operative index) or long-term (postdischarge).³ Long-term complications include implant loosening, instability, revision, infection, rotator cuff tear, neural injury, and deltoid detachment.^1,4,5 Perioperative complications, which are less commonly reported, include intraoperative fracture, infection, neural injury, venous thromboembolic events (VTEs, including pulmonary embolism [PE] and deep vein thrombosis [DVT]), transfusion, and death.^3,6-10

SA is an attractive treatment option for patients with rheumatoid arthritis (RA), as the effects of pain on these patients are greater in the shoulder joint than in any other joint.¹¹ Patients with RA pose unique orthopedic surgical challenges, including any combination of decreased bone mineralization, poor capsular tissue integrity, and osteonecrosis.^3,12 In addition, RA patients may be taking immunosuppressive medications that have severe side effects, and they may require multiple surgeries.^12,13 These factors predispose patients with RA to complications that include infection and wound dehiscence.^3,5,12-14

The complex nature of RA has prompted investigators to examine outcome measures in this patient group. Hambright and colleagues³ used the Nationwide Inpatient Sample (NIS) to examine perioperative outcomes in RA patients who underwent TSA between 1988 and 2005.³ They found that TSA patients with RA had shorter and less costly hospital stays and were more likely to have a routine discharge.³ Using the same patient population drawn from the period 2006–2011, we conducted a study to determine if this unexpected trend persists as the number of TSAs and quality of postoperative care continue to increase. Given the potential for anemia of chronic disease and the systemic inflammatory nature of RA, we hypothesized that the perioperative complication profile of RA patients would be worse than that of non-RA patients.

Materials and Methods

NIS data were acquired for the period 2006–2011. The NIS is the largest publicly available all-payer inpatient database, with a random 20% sample of about 1000 US hospitals accounting for 7 to 8 million inpatient stays. The database supplies weights used to estimate national totals, at about 35 million inpatient visits per year. NIS inpatient data are limited to the operative index. Postdischarge information is not available. The NIS is managed by the Healthcare Cost and Utilization Project, which is sponsored by the Agency for Healthcare Research and Quality. The quality of NIS data is assessed and validated by an independent contractor. NIS data have been widely used to examine perioperative outcomes.^15-17

NIS data cover patient and hospital demographics, hospital length of stay (LOS), discharge status, payer information, charges, and perioperative outcomes and procedure/diagnosis codes (ICD-9; International Classification of Diseases, Ninth Revision¹⁸).

As our Institutional Review Board (IRB) reviewed the database and determined the project was not human subject research, IRB involvement was not required. This study paralleled successful efforts with similar RA and non-RA patients who had shoulder and elbow surgery.^3,19 SA patients were identified by ICD-9 procedure code 81.80, but this code does not specify whether the prosthesis was unconstrained, semiconstrained, or constrained. ICD-9 coding also does not specify whether the TSA was traditional or reverse. Patients with RA were identified by ICD-9 diagnosis codes 714.0, 714.1, and 714.2. Patients without one of these codes were placed in the non-RA cohort. Patients with codes associated with pathologic fractures secondary to metastatic cancer or bone malignant neoplasm as a secondary or primary diagnosis and patients who had revision surgery indicated by code 81.83 were excluded, as they have a disproportionately higher comorbidity burden.

After each cohort was defined, demographic data (age, sex, race, income quartile based on ZIP postal code) were compared, as were data on primary payer, hospital demographics, LOS (≤5 days, defined as perioperative index), discharge type, inflation-adjusted charges in 2014 dollars based on the Consumer Price Indexes (http://www.bls.gov/cpi/), and mortality. Perioperative complications—respiratory, gastrointestinal, genitourinary, accidental puncture/laceration, central nervous system, wound dehiscence, device-related (including embolism, fibrosis, hemorrhage, pain, stenosis, or thrombus caused by any device, implant, or graft), cardiac, hematoma/seroma, acute respiratory distress syndrome, postoperative shock, VTE, postoperative infection complications, and intraoperative transfusions—were considered using ICD-9 codes (996.X-999.X and 99.X, respectively).²⁰ Although commonly used to determine perioperative comorbidity burden using ICD-9 coding, the modified Charlson index was not considered because RA is a component of the index and would therefore bias the variable.^3,21

Statistical analyses, including χ² tests and 2-sample t tests, were performed for categorical and continuous variables, respectively. P < .05 was considered significant. Fisher exact test was used for cohorts with fewer than 5 occurrences. Multivariate logistic regression models were then calculated to determine the effect of RA on different outcomes and complications, with age, race, sex, hospital region, hospital type, number of hospital beds, primary payer, and hospital ownership as covariates. Statistical analyses were performed using the R statistical programming language.22

Results

Of the 34,970 patients who underwent SA between 2006 and 2011, 1674 (4.8%) had a diagnosis of RA and 33,296 (95.2%) did not. On average, patients with RA tended to be younger than patients without RA (66.4 vs 69.1 years; P < .001), and a larger percentage of RA patients were female (75.5% vs 54.4%; P < .001). Compared with non-RA patients, RA patients comprised a different ethnic group and had a different expected primary payer (P < .001). SA patients with and without RA did not differ in income quartile based on ZIP code, total number of hospital beds, hospital region, or hospital teaching status (P = .34, .78, .59, and .82, respectively) (Table 1).

LOS was significantly (P < .001) statistically longer for RA patients (2.196 days) than for non-RA patients (2.085 days). RA patients were significantly less likely to be discharged home (63.0% vs 67.6%; P < .001). (Routine discharge was defined as discharge home, whereas nonroutine discharge was defined as discharge to a short-term hospital, skilled nursing facility, intermediate care, another type of facility, home health care, against medical advice, or death.) In addition, inflation-adjusted charges associated with SA were significantly higher (P = .018) for RA patients ($54,284) than for non-RA patients ($52,663) (Table 1).

Regarding the rates of complications that occurred during the perioperative index, there were no significant differences between RA and non-RA cohorts. These complications included respiratory, gastrointestinal, genitourinary, accidental puncture/laceration, central nervous system, wound dehiscence, device-related, cardiac, hematoma/seroma, acute respiratory distress syndrome, postoperative shock, VTE, and postoperative infection (Table 2). In addition, there was no significant difference in mortality between the groups (P = .48).

In TSA, blood transfusions were more likely (P < .001) to be given to RA patients (9.00%) than to non-RA patients (6.16%). Multivariate regression analyses were performed with age, race, sex, hospital region, hospital type, number of hospital beds, primary payer, and hospital ownership as covariates. These analyses revealed that transfusion (P < .001), discharge type (P = .002), total inflation-adjusted charges (P < .001), and LOS (P = .047) remained significant (Table 3).

Discussion

Large national databases like NIS allow study of uncommon medical occurrences and help delineate risks and trends that otherwise might be indeterminable. Although it has been suggested that patients with RA may have poorer long-term outcomes after SA, the perioperative risk profile indicates that TSA is well tolerated in RA patients during the operative index.^3,23-25

The data on this study’s 34,970 patients, drawn from the period 2006–2011, demonstrated no significant differences in safety profile with respect to the 14 perioperative complications and outcomes examined, except blood transfusion rate. Rates of postoperative infection (RA, 0.24%; non-RA, 0.14%; P = .303), VTE (RA, 0.30%; non-RA, 0.25%; P = .905), and transfusion (RA, 9.00%; non-RA, 6.16%; P < .001) are of particular interest because of the severity of these situations.

Postoperative infection is a potentially serious complication and often occurs secondary to diabetes, RA, lupus erythematosus, prior surgery, or a nosocomial or remote source.¹ The often costly treatment options include antibiotic suppression, irrigation and debridement with implant retention, 1-stage exchange with antibiotic-impregnated cement fixation, staged reimplantation, resection arthroplasty, arthrodesis, and amputation.¹ The overall 0.14% infection rate determined in this study is lower than the 0.7% reported for SA patients in the literature.¹ Given the nature of the NIS database, this rate underestimates the true postoperative infection rate, as any infection that occurred after the perioperative period is not captured.²⁶ The present study’s perioperative infection rates (RA, 0.24%; non-RA, 0.14%) for the period 2006–2011 are comparable to the rates (RA, 0.17%; non-RA, 0.24%) reported by Hambright and colleagues3 for the same patient population over the preceding, 18-year period (1988–2005) and similarly do not significantly differ between groups. Although infection is uncommon in the immediate perioperative period, the ICD-9 codes used refer specifically to infection resulting from surgery and do not represent concomitant infection.

VTEs, which include PEs and DVTs, are rare but potentially life-threatening surgical complications.^27,28 Mechanical prophylaxis and chemical prophylaxis have been recommended for major orthopedic surgery, particularly lower extremity surgery, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA).^28,29 In the present study, VTE rates were low, 0.30% (RA) and 0.25% (non-RA), and not significantly different in bivariate or multivariate analyses. These rates are comparable to those found in other national-database SA studies.²⁸ VTEs that occur outside the index hospital admission are not captured in this database. Therefore, the rates in the present study may be lower than the true incidence after SA. Mortality secondary to VTE usually occurs within 24 hours but may occur up to 90 days after surgery. DVT rates, on the other hand, are difficult to evaluate because of differences in screening practices.^27,28,30,31

That RA patients were more likely than non-RA patients to receive perioperative blood transfusions supports prior findings that SA patients with RA were more likely than SA patients with osteoarthritis (OA) to receive perioperative blood transfusions.⁸ RA patients have been shown to have high rates of anemia of chronic disease, ranging from 22% to 77%.³² During joint replacement, these patients often require transfusions.^32,33 However, these findings differ from prior findings of no differences between RA and non-RA patients in the same patient population during the period 1988–2005.³ This difference may be a product of the constantly changing transfusion guidelines and increased use; transfusion rates increased 140% between 1997 and 2007, making transfusions the fastest growing common procedure in the United States during that time.³⁴ There was no difference between RA and non-RA patients in household income (as determined by ZIP code analysis), number of hospital beds, hospital region, or hospital teaching status. Compared with non-RA patients, RA patients were more likely to be younger, female, and of a difference race and to have a different expected primary payer (P < .001).These findings are consistent with previous findings in the literature.³ In the present SA study, however, RA patients were more likely than non-RA patients to have longer LOS, higher inflation-adjusted hospital charges, and nonroutine discharge. These findings deviate from those of the study covering the preceding 18 years (1988–2005).³ Despite the findings of a changing environment of care for RA patients, by Hambright and colleagues³ and Weiss and colleagues,³⁵ the trend appears to have shifted. Both groups had shorter average LOS than either group from the preceding 18 years.³ Although statistically significant in bivariate analysis, the difference in LOS between the 2 groups differed by an average of 0.11 day (2 hours 24 minutes) and was not clinically relevant.

In addition, the higher charges for patients with RA represent a deviation from the preceding 18 years.³ Other studies have also shown that RA is associated with increased cost in TSA.³⁶ Patients with RA often have rotator cuff pathology, indicating reverse SA may be used more frequently.^37,38 The increased implant cost associated with reverse SA may account for the increased costs in RA patients.³⁹ As mentioned, TSA type is not captured in the NIS database. In addition, that RA patients were less likely than non-RA patients to have routine discharge may indicate RA cases are more complex because of their complications.^1,5,14,40 A recent study of complications in RA patients (1163 who underwent THA, 2692 who underwent TKA) found that THA patients with RA were significantly more likely than THA patients with OA to dislocate, and TKA patients with RA were significantly more likely than TKA patients with OA to develop an infection after surgery.⁴¹ Postoperative dislocation has been shown to increase hospital costs in other orthopedic procedures.⁴² Also, during TSA, patients with RA are more likely than patients with OA to receive intraoperative blood transfusions.⁸ These complications—combined with the fact that RA is a chronic, progressive, systemic inflammatory disease that can affect soft tissue and blood vessel wall healing and is associated with medications having potential side effects—could contribute to the apparent increased hospital charges and LOS.^3,12,13,43 Factors that include surgeon preference, impact of primary payer, and hospital practice may also affect final charges. Total charges in the NIS database include administrative fees, hospital costs, device-related costs, operating room costs, and ancillary staff costs. Total charges do not include professional fees and differ from the total cost that represents the amount reimbursed by the payer. Charges tend to correlate with but overestimate the total costs.⁴⁴

This study had several important limitations. As mentioned, only events that occur during the operative admission are captured in the NIS database, and thus postoperative complications or serious adverse events that lead to readmission cannot be identified. In addition, outpatient TSAs are not captured in the NIS database, and thus inclusion of only inpatient procedures yields higher average LOS and total charges.⁴⁵ Given the limited granularity of ICD-9 coding, this study could not determine RA severity, estimated blood loss, length of surgery, complication severity, type of TSA procedure/prosthesis, or cause of death. Although commonly used to determine comorbidity burden, the modified Charlson index could not be used, and therefore could not be entered as a covariate in multivariate analysis. Furthermore, the NIS database does not include imaging or patient-reported outcomes information, such as improvements in pain or function, which are of crucial importance in considering surgery.

Conclusion

Our findings corroborated findings that the demographics and the perioperative safety profile for TSA were similar for patients with and without RA. The risk for complications or death in the perioperative period was low. Compared with non-RA patients, RA patients had significantly higher charges and longer LOS and were less likely to be discharged home after surgery. The 0.11-day difference in LOS, though statistically significant, was not clinically relevant. These findings differ from those for the preceding, 18-year period (1988–2005). Future research should focus on the causes of these changes.

Linear Basal Cell Carcinoma

On examination, the lesion was suspected to be a nevocellular nevus, foreign body granuloma, or venous lake; however, a skin biopsy specimen from the lesion on the left wrist revealed a tumor mass of basaloid cells, peripheral palisading arrangement, and scattered pigment granules (Figure 1). Tumor cells were negative for S-100 protein staining. These findings were consistent with a diagnosis of linear basal cell carcinoma (BCC). The lesion was removed by simple excision with primary closure of the wound. The surgical margins were free of tumor cells. The lesion had not recurred at 6-month follow-up. The patient was subsequently lost to follow-up.

Basal cell carcinoma presents with diverse clinical features, and several morphologic and histologic variants have been reported.¹ Linear BCC was described as a distinct clinical entity in 1985 by Lewis² in a 73-year-old man with a 20-mm linear pigmented lesion on the left cheek. Linear BCC often is not recognized or categorized as such by clinicians, as some may think that linear BCC is not a distinct entity but rather is one of the diverse clinical features of BCC.³ Linear BCC is believed to have specific clinical and histologic features and can be regarded as a distinct entity.⁴ Mavrikakis et al⁵ objectively defined linear BCC as a lesion that appeared to extend preferentially in one direction, resulting in a lesion with relatively straight borders and a length much greater than the width (3:1 ratio). Our patient presented with a linearly curved lesion, which is a rare feature of BCC.

Linear BCC occurs in equal proportions in men and women aged 40 to 87 years. More than 92% of reported patients were older than 60 years.⁶ The most common site for linear BCC is the periocular area, with the majority of lesions occurring on the cheek or lower eyelid. The second most common site is the neck, followed by the trunk, lower face, and inguinal skin fold.^3,5

The mechanism of linearity has been speculated. The majority of the reported cases of linear BCC have no history of trauma.⁷ However, focal trauma has been assumed to be a risk factor for the development of linear BCC, so the possibility that the Köbner phenomenon may be related to its linear pattern has been proposed.⁸ The Köbner phenomenon can be implicated in our case, as there was a history of surgery, which resulted in a scar.

Menzies⁹ described dermoscopic features of pigmented BCC and stated that the diagnosis of pigmented BCC required the presence of 1 or more of the following 6 positive features: large blue-gray ovoid nests; multiple blue-gray globules; maple leaf–like areas; spoke wheel areas; ulceration; and arborizing treelike vessels. In our case, there were multiple blue-gray globules and a streak that resembled ginseng (Figure 2).

Linear BCC is an uncommon morphological variant that requires clinical recognition. Our case was unique because of the ginsenglike streak on dermoscopy and possible association with a prior trauma.

Linear Basal Cell Carcinoma

On examination, the lesion was suspected to be a nevocellular nevus, foreign body granuloma, or venous lake; however, a skin biopsy specimen from the lesion on the left wrist revealed a tumor mass of basaloid cells, peripheral palisading arrangement, and scattered pigment granules (Figure 1). Tumor cells were negative for S-100 protein staining. These findings were consistent with a diagnosis of linear basal cell carcinoma (BCC). The lesion was removed by simple excision with primary closure of the wound. The surgical margins were free of tumor cells. The lesion had not recurred at 6-month follow-up. The patient was subsequently lost to follow-up.

Basal cell carcinoma presents with diverse clinical features, and several morphologic and histologic variants have been reported.¹ Linear BCC was described as a distinct clinical entity in 1985 by Lewis² in a 73-year-old man with a 20-mm linear pigmented lesion on the left cheek. Linear BCC often is not recognized or categorized as such by clinicians, as some may think that linear BCC is not a distinct entity but rather is one of the diverse clinical features of BCC.³ Linear BCC is believed to have specific clinical and histologic features and can be regarded as a distinct entity.⁴ Mavrikakis et al⁵ objectively defined linear BCC as a lesion that appeared to extend preferentially in one direction, resulting in a lesion with relatively straight borders and a length much greater than the width (3:1 ratio). Our patient presented with a linearly curved lesion, which is a rare feature of BCC.

Linear BCC occurs in equal proportions in men and women aged 40 to 87 years. More than 92% of reported patients were older than 60 years.⁶ The most common site for linear BCC is the periocular area, with the majority of lesions occurring on the cheek or lower eyelid. The second most common site is the neck, followed by the trunk, lower face, and inguinal skin fold.^3,5

The mechanism of linearity has been speculated. The majority of the reported cases of linear BCC have no history of trauma.⁷ However, focal trauma has been assumed to be a risk factor for the development of linear BCC, so the possibility that the Köbner phenomenon may be related to its linear pattern has been proposed.⁸ The Köbner phenomenon can be implicated in our case, as there was a history of surgery, which resulted in a scar.

Menzies⁹ described dermoscopic features of pigmented BCC and stated that the diagnosis of pigmented BCC required the presence of 1 or more of the following 6 positive features: large blue-gray ovoid nests; multiple blue-gray globules; maple leaf–like areas; spoke wheel areas; ulceration; and arborizing treelike vessels. In our case, there were multiple blue-gray globules and a streak that resembled ginseng (Figure 2).

Linear BCC is an uncommon morphological variant that requires clinical recognition. Our case was unique because of the ginsenglike streak on dermoscopy and possible association with a prior trauma.

Linear Basal Cell Carcinoma

On examination, the lesion was suspected to be a nevocellular nevus, foreign body granuloma, or venous lake; however, a skin biopsy specimen from the lesion on the left wrist revealed a tumor mass of basaloid cells, peripheral palisading arrangement, and scattered pigment granules (Figure 1). Tumor cells were negative for S-100 protein staining. These findings were consistent with a diagnosis of linear basal cell carcinoma (BCC). The lesion was removed by simple excision with primary closure of the wound. The surgical margins were free of tumor cells. The lesion had not recurred at 6-month follow-up. The patient was subsequently lost to follow-up.

Basal cell carcinoma presents with diverse clinical features, and several morphologic and histologic variants have been reported.¹ Linear BCC was described as a distinct clinical entity in 1985 by Lewis² in a 73-year-old man with a 20-mm linear pigmented lesion on the left cheek. Linear BCC often is not recognized or categorized as such by clinicians, as some may think that linear BCC is not a distinct entity but rather is one of the diverse clinical features of BCC.³ Linear BCC is believed to have specific clinical and histologic features and can be regarded as a distinct entity.⁴ Mavrikakis et al⁵ objectively defined linear BCC as a lesion that appeared to extend preferentially in one direction, resulting in a lesion with relatively straight borders and a length much greater than the width (3:1 ratio). Our patient presented with a linearly curved lesion, which is a rare feature of BCC.

Linear BCC occurs in equal proportions in men and women aged 40 to 87 years. More than 92% of reported patients were older than 60 years.⁶ The most common site for linear BCC is the periocular area, with the majority of lesions occurring on the cheek or lower eyelid. The second most common site is the neck, followed by the trunk, lower face, and inguinal skin fold.^3,5

The mechanism of linearity has been speculated. The majority of the reported cases of linear BCC have no history of trauma.⁷ However, focal trauma has been assumed to be a risk factor for the development of linear BCC, so the possibility that the Köbner phenomenon may be related to its linear pattern has been proposed.⁸ The Köbner phenomenon can be implicated in our case, as there was a history of surgery, which resulted in a scar.

Menzies⁹ described dermoscopic features of pigmented BCC and stated that the diagnosis of pigmented BCC required the presence of 1 or more of the following 6 positive features: large blue-gray ovoid nests; multiple blue-gray globules; maple leaf–like areas; spoke wheel areas; ulceration; and arborizing treelike vessels. In our case, there were multiple blue-gray globules and a streak that resembled ginseng (Figure 2).

Linear BCC is an uncommon morphological variant that requires clinical recognition. Our case was unique because of the ginsenglike streak on dermoscopy and possible association with a prior trauma.

CHICAGO – Adding the cytokine IL-2 to front-line therapy with the anti-GD2 antibody ch14.18/CHO provided no additional survival benefit and only added to toxicity in the treatment of pediatric patients with high-risk neuroblastoma (NB), Dr. Ruth Ladenstein reported at the annual meeting of the American Society of Clinical Oncology.

A form of the antibody (dinutuximab) is approved for use in combination with granulocyte-macrophage colony stimulating factor, IL-2, and 13-cis-retinoic acid (RA) to treat high risk NB. A previous study (N Engl J Med. 2010;363:1324-34) showed that a combination of ch14.18 and the cytokines improved event free survival to 66% at 2 years, but the role of cytokines in this context remained unclear. Dr. Ladenstein and associates therefore performed a phase III trial that randomized patients to the antibody with or without subcutaneous (sc) IL-2.

High-risk NB was defined as patients with International Neuroblastoma Staging System stage 4 disease 1 year old or older, stage 4 less than 1 year old with MYCN amplification, or stage 2,3 patients up to age 21 years with MYCN amplification. Patients underwent a rapid induction therapy, followed by peripheral stem cell harvest, local control with complete tumor resection, myeloablative therapy with peripheral stem cell transplant, local control with radiotherapy, and then ch14.18 anti-GD2 monoclonal immunotherapy with RA, with or without sc IL-2.

Inclusion criteria were a complete response or partial response with three or fewer skeletal metastatic spots and no positive bone marrow biopsies on two aspirates. Randomization occurred between day 60 and 90 post stem cell infusion. RA was given on days 1-14 post randomization. For the arm receiving IL-2, it was given as 5 daily injections of 6 x 106 IU/m² per day over 8 hours on days 15-19. IL-2 was repeated on days 22-26. Both groups also received the ch14.18 antibody on days 22-26. All patients received high-dose morphine for pain management.

For event free survival (EFS), the primary endpoint of the trial, “if we look at 3 years, we see with antibody alone it’s 57%. With IL-2, it’s 60%. It’s completely clear that there’s no superiority for the IL-2 arm,” said Dr. Ladenstein, professor of pediatrics at the Children’s Cancer Research Institute, Austria.

At 5 years, the EFS was no different for the two treatment arms, at 51% for antibody alone and 56% for antibody plus IL-2 (P = .561). There were 199/200 patients in the antibody-alone arm with follow-up after randomization and 203/206 in the antibody plus IL-2 arm. The same was true for the secondary endpoint of overall survival, with 66% survival with antibody-alone and 58% in the antibody plus IL-2 at 5 years.

The EFS for patients with a complete response prior to immunotherapy was 66% at 3 years and was 50% for patients with less than a complete response, a significant difference (P = .003) in favor of those with a complete response. IL-2 administration had no effect on the EFS of the patients with a complete response if it was given with the immunotherapy. Similarly, IL-2 made no difference for patients who had had a very good partial response or a partial response prior to immunotherapy. For complete, very good partial, or partial responses prior to immunotherapy, the overall response to immunotherapy was 51%.

“However, feasibility is a concern, particularly in the IL-2 arm. Only 61% of the cycles were completed whereas it was 85% in the antibody-only arm, and the interruptions are definitely related mainly to the IL-2 component,” Dr. Ladenstein said.

Toxicity was higher for those patients receiving IL-2 compared to those getting antibody alone: Lansky performance status of 30% or less was 41% vs. 17%, early termination of therapy was 39% vs. 15%, and Common Terminology Criteria grade 3/4 fever was 41% vs. 14%, respectively (all P less than .001). There were also significantly more grade 3/4 allergic reactions and incidences of capillary leak, as well as diarrhea, hypotension, central nervous toxicity, and pain with IL-2.

The outcomes were favorable with antibody immunotherapy alone, but the higher toxicity with IL-2 shows that “a less toxic treatment schedule therefore is needed for this late treatment phase,” Dr. Ladenstein said.

Commenting on the trial, Dr. Barbara Hero of University Children’s Hospital in Cologne, Germany, asked whether cytokines are a useful part of the regimen “because we know the cytokines add quite a lot of toxicity to the regimens.” Even if they are potentially useful, researchers still do not know which cytokines, route of administration, and at what doses and timing would be best. Also, it is not known if a different induction regimen or antibody treatment could make a difference in using cytokines.

Another question is whether cytokines may be of benefit in patients with a higher tumor burden, e.g., more than three skeletal spots, used as the eligibility cut-off in this trial, Dr. Hero said.

CHICAGO – Adding the cytokine IL-2 to front-line therapy with the anti-GD2 antibody ch14.18/CHO provided no additional survival benefit and only added to toxicity in the treatment of pediatric patients with high-risk neuroblastoma (NB), Dr. Ruth Ladenstein reported at the annual meeting of the American Society of Clinical Oncology.

A form of the antibody (dinutuximab) is approved for use in combination with granulocyte-macrophage colony stimulating factor, IL-2, and 13-cis-retinoic acid (RA) to treat high risk NB. A previous study (N Engl J Med. 2010;363:1324-34) showed that a combination of ch14.18 and the cytokines improved event free survival to 66% at 2 years, but the role of cytokines in this context remained unclear. Dr. Ladenstein and associates therefore performed a phase III trial that randomized patients to the antibody with or without subcutaneous (sc) IL-2.

High-risk NB was defined as patients with International Neuroblastoma Staging System stage 4 disease 1 year old or older, stage 4 less than 1 year old with MYCN amplification, or stage 2,3 patients up to age 21 years with MYCN amplification. Patients underwent a rapid induction therapy, followed by peripheral stem cell harvest, local control with complete tumor resection, myeloablative therapy with peripheral stem cell transplant, local control with radiotherapy, and then ch14.18 anti-GD2 monoclonal immunotherapy with RA, with or without sc IL-2.

Inclusion criteria were a complete response or partial response with three or fewer skeletal metastatic spots and no positive bone marrow biopsies on two aspirates. Randomization occurred between day 60 and 90 post stem cell infusion. RA was given on days 1-14 post randomization. For the arm receiving IL-2, it was given as 5 daily injections of 6 x 106 IU/m² per day over 8 hours on days 15-19. IL-2 was repeated on days 22-26. Both groups also received the ch14.18 antibody on days 22-26. All patients received high-dose morphine for pain management.

For event free survival (EFS), the primary endpoint of the trial, “if we look at 3 years, we see with antibody alone it’s 57%. With IL-2, it’s 60%. It’s completely clear that there’s no superiority for the IL-2 arm,” said Dr. Ladenstein, professor of pediatrics at the Children’s Cancer Research Institute, Austria.

At 5 years, the EFS was no different for the two treatment arms, at 51% for antibody alone and 56% for antibody plus IL-2 (P = .561). There were 199/200 patients in the antibody-alone arm with follow-up after randomization and 203/206 in the antibody plus IL-2 arm. The same was true for the secondary endpoint of overall survival, with 66% survival with antibody-alone and 58% in the antibody plus IL-2 at 5 years.

The EFS for patients with a complete response prior to immunotherapy was 66% at 3 years and was 50% for patients with less than a complete response, a significant difference (P = .003) in favor of those with a complete response. IL-2 administration had no effect on the EFS of the patients with a complete response if it was given with the immunotherapy. Similarly, IL-2 made no difference for patients who had had a very good partial response or a partial response prior to immunotherapy. For complete, very good partial, or partial responses prior to immunotherapy, the overall response to immunotherapy was 51%.

“However, feasibility is a concern, particularly in the IL-2 arm. Only 61% of the cycles were completed whereas it was 85% in the antibody-only arm, and the interruptions are definitely related mainly to the IL-2 component,” Dr. Ladenstein said.

Toxicity was higher for those patients receiving IL-2 compared to those getting antibody alone: Lansky performance status of 30% or less was 41% vs. 17%, early termination of therapy was 39% vs. 15%, and Common Terminology Criteria grade 3/4 fever was 41% vs. 14%, respectively (all P less than .001). There were also significantly more grade 3/4 allergic reactions and incidences of capillary leak, as well as diarrhea, hypotension, central nervous toxicity, and pain with IL-2.

The outcomes were favorable with antibody immunotherapy alone, but the higher toxicity with IL-2 shows that “a less toxic treatment schedule therefore is needed for this late treatment phase,” Dr. Ladenstein said.

Commenting on the trial, Dr. Barbara Hero of University Children’s Hospital in Cologne, Germany, asked whether cytokines are a useful part of the regimen “because we know the cytokines add quite a lot of toxicity to the regimens.” Even if they are potentially useful, researchers still do not know which cytokines, route of administration, and at what doses and timing would be best. Also, it is not known if a different induction regimen or antibody treatment could make a difference in using cytokines.

Another question is whether cytokines may be of benefit in patients with a higher tumor burden, e.g., more than three skeletal spots, used as the eligibility cut-off in this trial, Dr. Hero said.

CHICAGO – Adding the cytokine IL-2 to front-line therapy with the anti-GD2 antibody ch14.18/CHO provided no additional survival benefit and only added to toxicity in the treatment of pediatric patients with high-risk neuroblastoma (NB), Dr. Ruth Ladenstein reported at the annual meeting of the American Society of Clinical Oncology.

A form of the antibody (dinutuximab) is approved for use in combination with granulocyte-macrophage colony stimulating factor, IL-2, and 13-cis-retinoic acid (RA) to treat high risk NB. A previous study (N Engl J Med. 2010;363:1324-34) showed that a combination of ch14.18 and the cytokines improved event free survival to 66% at 2 years, but the role of cytokines in this context remained unclear. Dr. Ladenstein and associates therefore performed a phase III trial that randomized patients to the antibody with or without subcutaneous (sc) IL-2.

High-risk NB was defined as patients with International Neuroblastoma Staging System stage 4 disease 1 year old or older, stage 4 less than 1 year old with MYCN amplification, or stage 2,3 patients up to age 21 years with MYCN amplification. Patients underwent a rapid induction therapy, followed by peripheral stem cell harvest, local control with complete tumor resection, myeloablative therapy with peripheral stem cell transplant, local control with radiotherapy, and then ch14.18 anti-GD2 monoclonal immunotherapy with RA, with or without sc IL-2.

Inclusion criteria were a complete response or partial response with three or fewer skeletal metastatic spots and no positive bone marrow biopsies on two aspirates. Randomization occurred between day 60 and 90 post stem cell infusion. RA was given on days 1-14 post randomization. For the arm receiving IL-2, it was given as 5 daily injections of 6 x 106 IU/m² per day over 8 hours on days 15-19. IL-2 was repeated on days 22-26. Both groups also received the ch14.18 antibody on days 22-26. All patients received high-dose morphine for pain management.

For event free survival (EFS), the primary endpoint of the trial, “if we look at 3 years, we see with antibody alone it’s 57%. With IL-2, it’s 60%. It’s completely clear that there’s no superiority for the IL-2 arm,” said Dr. Ladenstein, professor of pediatrics at the Children’s Cancer Research Institute, Austria.

At 5 years, the EFS was no different for the two treatment arms, at 51% for antibody alone and 56% for antibody plus IL-2 (P = .561). There were 199/200 patients in the antibody-alone arm with follow-up after randomization and 203/206 in the antibody plus IL-2 arm. The same was true for the secondary endpoint of overall survival, with 66% survival with antibody-alone and 58% in the antibody plus IL-2 at 5 years.

The EFS for patients with a complete response prior to immunotherapy was 66% at 3 years and was 50% for patients with less than a complete response, a significant difference (P = .003) in favor of those with a complete response. IL-2 administration had no effect on the EFS of the patients with a complete response if it was given with the immunotherapy. Similarly, IL-2 made no difference for patients who had had a very good partial response or a partial response prior to immunotherapy. For complete, very good partial, or partial responses prior to immunotherapy, the overall response to immunotherapy was 51%.

“However, feasibility is a concern, particularly in the IL-2 arm. Only 61% of the cycles were completed whereas it was 85% in the antibody-only arm, and the interruptions are definitely related mainly to the IL-2 component,” Dr. Ladenstein said.

Toxicity was higher for those patients receiving IL-2 compared to those getting antibody alone: Lansky performance status of 30% or less was 41% vs. 17%, early termination of therapy was 39% vs. 15%, and Common Terminology Criteria grade 3/4 fever was 41% vs. 14%, respectively (all P less than .001). There were also significantly more grade 3/4 allergic reactions and incidences of capillary leak, as well as diarrhea, hypotension, central nervous toxicity, and pain with IL-2.

The outcomes were favorable with antibody immunotherapy alone, but the higher toxicity with IL-2 shows that “a less toxic treatment schedule therefore is needed for this late treatment phase,” Dr. Ladenstein said.

Commenting on the trial, Dr. Barbara Hero of University Children’s Hospital in Cologne, Germany, asked whether cytokines are a useful part of the regimen “because we know the cytokines add quite a lot of toxicity to the regimens.” Even if they are potentially useful, researchers still do not know which cytokines, route of administration, and at what doses and timing would be best. Also, it is not known if a different induction regimen or antibody treatment could make a difference in using cytokines.

Another question is whether cytokines may be of benefit in patients with a higher tumor burden, e.g., more than three skeletal spots, used as the eligibility cut-off in this trial, Dr. Hero said.

The VA has proposed a significant rule change that would grant full practice authority to advanced practice registered nurses (APRNs). According to the VA, this stated goal will “increase veterans’ access to VA health care by expanding the pool of qualified health care professionals who are authorized to provide primary health care and other related health care services.” The change permits APRNs, nurse practitioners who have completed at least a master’s degree in nursing, to assess and diagnose patients, prescribe medications, and interpret diagnostic tests.

“This is good news for our APRNs, who will be able to perform functions that their colleagues in the private sector are already doing,” Under Secretary of Health David J. Shulkin, said in a statement.

The proposed role of APRNs is not unique in federal health care systems. The Army, Navy, Air Force, and Indian Health Service already give APRNs full practice authority.

The rule is open for comment through July 25, 2016, and has already received nearly 20,000 comments. Physician organizations have been particularly critical of the proposed change. “We believe that providing physician-led, patient-centered, team-based patient care is the best approach to improving quality care for our country's veterans. We feel this proposal will significantly undermine the delivery of care within the VA,” the American Medical Association noted in a statement.

Many of the most critical comments concerned the role of certified nurse anesthetists (CRNAs). The American Society of Anesthesiologists strongly criticized the rule, and of the comments to date, 15,906 specifically reference anesthesia.

Dr. Shulkin suggested that much of the criticism was misinformed. “I do not believe they [physicians] understand what our intent in going into this rule-making is,” he told The Washington Post. “We have embraced team-based health care. We believe in the model. We are not looking to destroy that. We are looking to add to our ability to deliver heath care to veterans in places that don’t frankly have health care for them right now.”

Echoing Dr. Shulkin’s comments, the Nurses Organization of Veteran Affairs (NOVA) and other nursing organizations fully support the rule. “The recognition of APRNs as full practice providers will continue to support the current VA team model of care,” Teresa Morris, NOVA director of advocacy & government relations explained. “In this model, each team member is working at the top of his or her education, training and expertise.”

According to Morris, the expanded role for APRNs also may help address disparities in care within the VA system. “There has been a lack of uniformity between VA networks, which can lead to confusion throughout the system and can contribute to issues in relationship to access,” she said. “We believe that this proposed change is resource driven and will help to decrease the variability in care provided by APRNs throughout the VA system.”

The VA has proposed a significant rule change that would grant full practice authority to advanced practice registered nurses (APRNs). According to the VA, this stated goal will “increase veterans’ access to VA health care by expanding the pool of qualified health care professionals who are authorized to provide primary health care and other related health care services.” The change permits APRNs, nurse practitioners who have completed at least a master’s degree in nursing, to assess and diagnose patients, prescribe medications, and interpret diagnostic tests.

“This is good news for our APRNs, who will be able to perform functions that their colleagues in the private sector are already doing,” Under Secretary of Health David J. Shulkin, said in a statement.

The proposed role of APRNs is not unique in federal health care systems. The Army, Navy, Air Force, and Indian Health Service already give APRNs full practice authority.

The rule is open for comment through July 25, 2016, and has already received nearly 20,000 comments. Physician organizations have been particularly critical of the proposed change. “We believe that providing physician-led, patient-centered, team-based patient care is the best approach to improving quality care for our country's veterans. We feel this proposal will significantly undermine the delivery of care within the VA,” the American Medical Association noted in a statement.

Many of the most critical comments concerned the role of certified nurse anesthetists (CRNAs). The American Society of Anesthesiologists strongly criticized the rule, and of the comments to date, 15,906 specifically reference anesthesia.

Dr. Shulkin suggested that much of the criticism was misinformed. “I do not believe they [physicians] understand what our intent in going into this rule-making is,” he told The Washington Post. “We have embraced team-based health care. We believe in the model. We are not looking to destroy that. We are looking to add to our ability to deliver heath care to veterans in places that don’t frankly have health care for them right now.”

Echoing Dr. Shulkin’s comments, the Nurses Organization of Veteran Affairs (NOVA) and other nursing organizations fully support the rule. “The recognition of APRNs as full practice providers will continue to support the current VA team model of care,” Teresa Morris, NOVA director of advocacy & government relations explained. “In this model, each team member is working at the top of his or her education, training and expertise.”

According to Morris, the expanded role for APRNs also may help address disparities in care within the VA system. “There has been a lack of uniformity between VA networks, which can lead to confusion throughout the system and can contribute to issues in relationship to access,” she said. “We believe that this proposed change is resource driven and will help to decrease the variability in care provided by APRNs throughout the VA system.”

The VA has proposed a significant rule change that would grant full practice authority to advanced practice registered nurses (APRNs). According to the VA, this stated goal will “increase veterans’ access to VA health care by expanding the pool of qualified health care professionals who are authorized to provide primary health care and other related health care services.” The change permits APRNs, nurse practitioners who have completed at least a master’s degree in nursing, to assess and diagnose patients, prescribe medications, and interpret diagnostic tests.

“This is good news for our APRNs, who will be able to perform functions that their colleagues in the private sector are already doing,” Under Secretary of Health David J. Shulkin, said in a statement.

The proposed role of APRNs is not unique in federal health care systems. The Army, Navy, Air Force, and Indian Health Service already give APRNs full practice authority.

The rule is open for comment through July 25, 2016, and has already received nearly 20,000 comments. Physician organizations have been particularly critical of the proposed change. “We believe that providing physician-led, patient-centered, team-based patient care is the best approach to improving quality care for our country's veterans. We feel this proposal will significantly undermine the delivery of care within the VA,” the American Medical Association noted in a statement.

Many of the most critical comments concerned the role of certified nurse anesthetists (CRNAs). The American Society of Anesthesiologists strongly criticized the rule, and of the comments to date, 15,906 specifically reference anesthesia.

Dr. Shulkin suggested that much of the criticism was misinformed. “I do not believe they [physicians] understand what our intent in going into this rule-making is,” he told The Washington Post. “We have embraced team-based health care. We believe in the model. We are not looking to destroy that. We are looking to add to our ability to deliver heath care to veterans in places that don’t frankly have health care for them right now.”

Echoing Dr. Shulkin’s comments, the Nurses Organization of Veteran Affairs (NOVA) and other nursing organizations fully support the rule. “The recognition of APRNs as full practice providers will continue to support the current VA team model of care,” Teresa Morris, NOVA director of advocacy & government relations explained. “In this model, each team member is working at the top of his or her education, training and expertise.”

According to Morris, the expanded role for APRNs also may help address disparities in care within the VA system. “There has been a lack of uniformity between VA networks, which can lead to confusion throughout the system and can contribute to issues in relationship to access,” she said. “We believe that this proposed change is resource driven and will help to decrease the variability in care provided by APRNs throughout the VA system.”